

GlaxoSmithKline Finance plc
(Registered number: 00242686)

Annual Report

for the year ended 31 December 2018

Registered office address:

980 Great West Road
Brentford
Middlesex
TW8 9GS

SATURDAY



A86QE12J

A10

01/06/2019

#360

COMPANIES HOUSE

GlaxoSmithKline Finance plc

Annual Report

for the year ended 31 December 2018

Contents

	Pages
Strategic report	1
Directors' report	2-4
Independent auditors' report	5-6
Income statement	7
Statement of other comprehensive income	8
Balance sheet	9
Statement of changes in equity	10
Notes to the financial statements	11-35

GlaxoSmithKline Finance plc
(Registered number: 00242686)

Strategic report for the year ended 31 December 2018

The Directors present their Strategic report on GlaxoSmithKline Finance plc (the "Company") for the year ended 31 December 2018.

Principal activities and future developments

The Company is a member of the GlaxoSmithKline Group (the "Group"). The principal activities of the Company during the financial year were the provision of financial services to other companies within the Group, including borrowing through the issue of short-term securities and investing in short-term securities in order to manage the liquidity requirements of Group undertakings. The Company also uses a variety of derivative financial instruments to manage the Group's foreign exchange and interest rate risks.

The Directors do not envisage any change to the nature of the business in the foreseeable future.

Review of business

The Company made a profit for the financial year of £2,616,944,000 (2017: £10,134,821,000), which will be transferred to reserves. The Directors are of the opinion that the current level of activity and the year end financial position are satisfactory and will remain so in the foreseeable future.

On 1 June 2018, the Group completed the transaction with Novartis AG ("Novartis") to buy out Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for \$13 billion (£9.2 billion). The Company used derivative financial instruments to manage the Group's foreign exchange risk arising from this transaction generating a gain of £302,763,000 (2017: £nil).

Principal risks and uncertainties

The Directors of GlaxoSmithKline plc manage the risks of the Group at a group level, rather than at an individual statutory entity level. For this reason, the Company's Directors believe that a discussion of the Group's risks would not be appropriate for an understanding of the development, performance or position of the Company's business. The principal risks and uncertainties of the Group, which include those of the Company, are discussed in the Group's 2018 Annual Report which does not form part of this report.


Key performance indicators (KPIs)

The Directors of the Group manage the Group's operations on an operating segment basis. For this reason, the Company's Directors believe that analysis using key performance indicators for the Company is not necessary or appropriate for an understanding of the development, performance or position of the Company's business. The development, performance and position of the Group are discussed in the Group's 2018 Annual Report which does not form part of this report.

Approach to Brexit

In preparing for the UK's exit from the EU (Brexit), the Directors of the Group have taken a risk-based approach to maintain continuity of supply of our medicines, vaccines and consumer healthcare products to the people in the UK and EU at the Group level, rather than at an individual statutory entity level. For this reason, the Company's Directors believe that a discussion of the Group's approach to Brexit would not be appropriate for an understanding of the impact of Brexit to the position of the Company's business. The Group's approach to Brexit, which includes that of the Company, are discussed in the Group's 2018 annual report which does not form part of this report.

On behalf of the Board


Mr A Walker
Director
24 May 2019

GlaxoSmithKline Finance plc
(Registered number: 00242686)

Directors' report for the year ended 31 December 2018

The Directors present their report on GlaxoSmithKline Finance plc (the "Company") and the audited financial statements for the year ended 31 December 2018.

Results and dividends

The Company's results for the financial year are shown in the income statement on page 7.

The Company declared a dividend of £10,000,000,000 (55.96p per ordinary share) on 21 June 2018 in respect of the financial year ended 31 December 2017 (2017: £10,000,000,000 (55.96p per ordinary share), declared and paid on 27 June 2017 in respect of the financial year ended 31 December 2016).

No dividend is proposed to the holders of ordinary shares in respect of the financial year ended 31 December 2018.

Financial instruments

The Company has entered into foreign exchange forward contracts and swaps in order to swap US commercial paper issuances, intercompany loans and deposits into the Company's functional currency. The Company has also entered into foreign exchange forward contracts and swaps on behalf of entities within the Group to hedge foreign exchange risk arising from various trade payables and receivables balances that are not denominated in the Company's own reporting currency. Details of financial risk management are disclosed in Note 5.

Directors and their interests

The Directors of the Company who were in office during the year and up to the date of signing the financial statements were as follows:

Mr A Walker	(appointed 11 February 2019)
Mr S Dingemans	(resigned 1 May 2019)
Dr S Vicentini	(resigned 11 February 2019)
Edinburgh Pharmaceutical Industries Limited	
Glaxo Group Limited	
The Wellcome Foundation Limited	

No Director had, during the year or at the end of the year, any material interest in any contract of significance to the Company's business with the exception of the Corporate Directors, where such an interest may arise in the ordinary course of business. A corporate director is a legal entity of the Group as opposed to a natural person (an individual) director.

Directors' indemnity

Each of the Directors benefits from an indemnity given by the Company under its articles of association. This indemnity is in respect of liabilities incurred by the Director in the execution and discharge of their duties.

In addition, each Director who is an individual benefits from an indemnity in respect of liabilities arising out of third party proceedings to which he is a party by reason of his engagement in the business of the Group. Furthermore, the Company has provided indemnities to those of its employees who serve as Directors of certain other Group undertakings. These indemnities are also in respect of liabilities arising out of third party proceedings to which the relevant individual is a party by reason of their engagement in the business of the Group undertaking.

GlaxoSmithKline Finance plc
(Registered number: 00242686)

Directors' report for the year ended 31 December 2018

Statement of Directors' responsibilities in respect of the financial statements

The Directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 101 "Reduced Disclosure Framework", and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards, comprising FRS 101, have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. The Directors are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The following items have been included in the Strategic report on page 1:

- principal activities and future developments;
- review of business;
- principal risks and uncertainties;
- key performance indicators; and
- approach to Brexit.

Governance

The Company's approach to the Modern Slavery Act 2015 is set by the Group. Each year, as part of their governance arrangements, the Group formally reviews and approves the approach to the Modern Slavery Act 2015 and has confirmed that the approach is still valid for 2018.

Disclosure of information to auditors

As far as each of the Directors are aware, there is no relevant audit information of which the Company's auditors are unaware, and the Directors have taken all the steps that ought to have been taken as a director to make themselves aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

GlaxoSmithKline Finance plc
(Registered number: 00242686)

Directors' report for the year ended 31 December 2018

Going concern

The Directors believe that preparing the financial statements on the going concern basis is appropriate due to the continued financial support of the ultimate parent company, GlaxoSmithKline plc. The Directors have received confirmation that GlaxoSmithKline plc intends to support the Company for at least one year after these financial statements are signed. For this reason, they continue to adopt the going concern basis in preparing the financial statements.


Independent auditors

PricewaterhouseCoopers LLP resigned on 16 October 2018 as the Company's auditors. Deloitte LLP have been appointed to act as the Company's auditors by a resolution of the Board of Directors in accordance with s489(3) Companies Act 2006. A resolution of the members to appoint Deloitte LLP as auditors was passed at the Annual General Meeting of the Company in accordance with s489(4) Companies Act 2006.

Post balance sheet event

On 23 May 2019, GlaxoSmithKline Holdings Limited undertook a share for share exchange whereby it subscribed for one ordinary share in the Company of £1 at a share premium of £8.9 billion in consideration for the transfer of US\$11.5 billion of its preference shares in Setfirst Limited to the Company. The US\$11.5 billion preference shares were redenominated to GBP preference shares and subdivided into shares with a nominal value of £1 each. These preference shares held by the Company in Setfirst Limited were redesignated as GBP ordinary shares and eliminated via capital reduction.

On behalf of the Board



Mr A Walker
Director
24 May 2019

Independent auditors' report to the members of GlaxoSmithKline Finance plc

Report on the audit of the financial statements

Opinion

In our opinion the financial statements of GlaxoSmithKline Finance plc (the "Company"):

- give a true and fair view of the state of the Company's affairs as at 31 December 2018 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 101 "Reduced Disclosure Framework"; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements which comprise:

- the income statement for the year ended 31st December 2018;
- the statement of other comprehensive income for the period;
- balance sheet as at 31 December 2018;
- the statement of changes in equity for the period; and
- the related notes 1 to 29 in the financial statements.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 101 "Reduced Disclosure Framework" (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council's (the "FRC's") Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We are required by ISAs (UK) to report in respect of the following matters where:

- the directors' use of the going concern basis of accounting in preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

We have nothing to report in respect of these matters.

Other information

The directors are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in respect of these matters.

Independent auditors' report to the members of GlaxoSmithKline Finance plc

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Report on other legal and regulatory requirements

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Strategic report or the Directors' report.

Matters on which we are required to report by exception

Under the Companies Act 2006 we are required to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns.
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

The Company has passed a resolution in accordance with section 506 of the Companies Act 2006 that the senior statutory auditor's name should not be stated.

Deloitte LLP

Deloitte LLP
Statutory Auditors
London, United Kingdom
24 May 2019

GlaxoSmithKline Finance plc

Income statement for the year ended 31 December 2018

	Note	2018 £'000	2017 £'000
Turnover	8	69,119	84,262
Gross profit		69,119	84,262
Other operating expense		(8,606)	(4,665)
Finance income	10	797,651	559,511
Finance expenses	11	(658,672)	(472,943)
Exchange gains on foreign currency transactions		302,763	-
Operating profit	12	502,255	166,165
Income from subsidiaries	13	2,210,107	10,000,000
Profit before taxation		2,712,362	10,166,165
Tax on profit	14	(95,418)	(31,344)
Profit for the financial year		2,616,944	10,134,821

The results disclosed above for both the current year and prior year relate entirely to continuing operations.

The notes on pages 11 to 35 are an integral part of these financial statements.

GlaxoSmithKline Finance plc

Statement of other comprehensive income for the year ended 31 December 2018

	2018 £'000	2017 £'000
Profit for the financial year	2,616,944	10,134,821
Items that may be subsequently reclassified to the income statement:		
Reclassification of cash flow hedges to the income statement	(25)	(2,901)
Deferred tax on fair value movements on cash flow hedges	4	409
Total comprehensive income for the financial year	2,616,923	10,132,329

The notes on pages 11 to 35 are an integral part of these financial statements.


GlaxoSmithKline Finance plc

Balance sheet as at 31 December 2018

	Note	2018 £'000	2017 £'000
Non-current assets			
Investments in subsidiaries	15	46,875,633	46,875,633
Derivative financial instruments	19	65,642	-
Trade and other receivables	16	3,070,480	1,464,766
Deferred tax assets	14	553	641
Total non-current assets		50,012,308	48,341,040
Current assets			
Trade and other receivables	16	83,999,883	86,114,168
Prepayments and accrued income	18	18,516	7,475
Derivative financial instruments	19	251,526	80,671
Cash and cash equivalents	20	1,995,323	466,914
Total current assets		86,265,248	86,669,228
Total assets		136,277,556	135,010,268
Current liabilities			
Trade and other payables	17	(74,222,450)	(67,372,878)
Short-term borrowings	21	(12,297)	(1,404)
Derivative financial instruments	19	(192,025)	(83,303)
Accruals and deferred income	22	(143,812)	(135,830)
Total current liabilities		(74,570,584)	(67,593,415)
Net current assets		11,694,664	19,075,813
Total assets less current liabilities		61,706,972	67,416,853
Non-current liabilities			
Long-term borrowings	21	(7,802,372)	(6,130,327)
Derivative financial instruments	19	(1,151)	-
Total non-current liabilities		(7,803,523)	(6,130,327)
Total liabilities		(82,374,107)	(73,723,742)
Net assets		53,903,449	61,286,526
Equity			
Called up share capital	23	17,870,000	17,870,000
Capital reserve		4,167,043	4,167,043
Cash flow hedge reserve		-	21
Retained earnings		31,866,406	39,249,462
Total equity		53,903,449	61,286,526

The notes on pages 11 to 35 are an integral part of these financial statements.

The financial statements on pages 7 to 35 were approved by the Board of Directors on 24 May 2019 and signed on its behalf by:



Mr A Walker
Director

GlaxoSmithKline Finance plc

Statement of changes in equity
for the year ended 31 December 2018

	Note	Called up share capital £'000	Capital reserve £'000	Cash flow hedge reserve £'000	Retained earnings £'000	Total equity £'000
At 1 January 2017		17,870,000	4,167,043	2,513	39,114,641	61,154,197
Profit for the financial year		-	-	-	10,134,821	10,134,821
Dividends to shareholders	24	-	-	-	(10,000,000)	(10,000,000)
Other comprehensive expense		-	-	(2,492)	-	(2,492)
At 31 December 2017		17,870,000	4,167,043	21	39,249,462	61,286,526
Profit for the financial year		-	-	-	2,616,944	2,616,944
Dividends to shareholders	24	-	-	-	(10,000,000)	(10,000,000)
Other comprehensive expense		-	-	(21)	-	(21)
At 31 December 2018		17,870,000	4,167,043	-	31,866,406	53,903,449

The notes on pages 11 to 35 are an integral part of these financial statements.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

1 Presentation of the financial statements

General information

GlaxoSmithKline Finance plc (the "Company") is a member of the GlaxoSmithKline Group of companies (the "Group") and provides financial services to other companies within the Group, including borrowing through the issue of short-term securities and investing in short-term securities in order to manage the liquidity requirements of Group undertakings. The Company also uses a variety of derivative financial instruments to manage the Group's foreign exchange and interest rate risks.

The Company is a public company and is incorporated and domiciled in the UK (England). The address of the registered office is 980 Great West Road, Brentford, Middlesex TW8 9GS.

2 Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied, unless otherwise stated.

(a) Basis of preparation

The financial statements have been prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework ("FRS 101").

Going concern

These financial statements have been prepared on the going concern basis, under the historical cost convention as modified by the revaluation of derivative financial assets and liabilities at fair value through profit or loss and in accordance with the Companies Act 2006 as applicable to companies using FRS 101.

Disclosure exemptions adopted

In preparing these financial statements, the Company has taken advantage of some of the disclosure exemptions conferred by FRS 101. Therefore these financial statements do not include:

- Paragraph 38 of IAS 1 "Presentation of financial statements" comparative information requirements in respect of:
 - paragraph 79(a) (iv) of IAS 1;
- The following paragraphs of IAS 1 "Presentation of financial statements":
 - 10(d) (statement of cash flows);
 - 16 (statement of compliance with all IFRS);
 - 38A (requirements for minimum of two primary statements, including cash flow statements); and
 - 111 (cash flow statement information);
- IAS 7 "Statement of cash flows";
- Paragraph 30 and 31 of IAS 8 "Accounting policies, changes in accounting estimates and errors" (requirement for the disclosure of information when an entity has not applied a new IFRS that has been issued but is not yet effective);
- Paragraph 17 of IAS 24 "Related party disclosures" (key management compensation); and
- The requirements in IAS 24 "Related party disclosures" to disclose related party transactions entered into between two or more wholly owned members of a group.

The financial statements of GlaxoSmithKline plc can be obtained as described in Note 2(b).

The preparation of financial statements in conformity with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in Notes 3 and 4.

(b) Consolidation

The Company is a wholly owned subsidiary of the ultimate parent company and as such has taken advantage of the exemption from preparing group financial statements under section 400 of the Companies Act 2006. GlaxoSmithKline plc, a company registered in England and Wales, is the Company's ultimate parent undertaking and controlling party. The largest and smallest group of undertakings for which group financial statements are prepared and which include the results of the Company, are the consolidated financial statements of GlaxoSmithKline plc. Copies of the consolidated financial statements can be obtained from the Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex TW8 9GS. The immediate parent undertaking is GlaxoSmithKline Holdings Limited. These financial statements are separate financial statements.

(c) Implementation of IFRS 9 "Financial instruments"

The Company has applied IFRS 9 "Financial instruments" with effect from 1 January 2018. IFRS 9 introduces new requirements for the classification and measurement of financial assets and financial liabilities, impairments for financial assets and general hedge accounting. Details of these new requirements as well as their impact on the Company's financial statements are described below. The Company has adopted IFRS 9 retrospectively but with certain permitted exceptions as detailed below.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

2 Summary of significant accounting policies (continued)

(c) Implementation of IFRS 9 "Financial instruments" (continued)

Classification and measurement of financial assets

The date of initial application was 1 January 2018. The Company has not applied the requirements of IFRS 9 to instruments that were derecognised prior to 1 January 2018 and has not restated prior years.

All financial assets that are within the scope of IFRS 9 are required to be measured at amortised cost or fair value with movements through other comprehensive income or the income statement on the basis of the Company's business model for managing the financial assets and the contractual cash flow characteristics of the financial assets.

The Company's trade and other receivables were all previously classified as financial assets measured at amortised cost. Under IFRS 9, as the contractual cash flows are solely payments of principal and interest on the principal amount outstanding, the amounts receivable are measured at amortised cost.

Investments in money market funds, included in cash and cash equivalents, that were previously classified as amortised cost financial assets have been classified as fair value through profit or loss under IFRS 9 as the contractual cash flows are not solely payments of principal and interest on the principal amount outstanding.

There were no material changes in the carrying value of the financial assets as a result of these changes in measurement basis.

Impairment of financial assets

IFRS 9 requires an expected credit loss ("ECL") model to be applied to financial assets rather than the incurred credit loss model. The expected credit loss model requires the Company to account for expected losses as a result of credit risk on initial recognition of financial assets and to recognise changes in those expected credit losses at each reporting date.

12-month ECLs are applied to all financial assets not measured at fair value through profit or loss. There were no other transition adjustments arising from the change in impairment basis.

General hedge accounting

The new general hedge accounting requirements retain the three types of hedge accounting which were available under IAS 39: fair value hedges, cash flow hedges, and net investment hedges. However, the effectiveness testing requirements have been simplified.

The Company has applied the IFRS 9 hedge accounting requirements prospectively from the date of initial application of 1 January 2018.

(d) Foreign currency transactions

Foreign currency transactions are booked in the functional currency of the Company at the exchange rate ruling on the date of the transaction. Foreign currency monetary assets and liabilities are translated into the functional currency at rates of exchange ruling at the balance sheet date. Exchange differences are included in the income statement. The functional and presentation currency of the Company is Pounds Sterling.

(e) Turnover

Turnover represents internal margins made on Treasury activities within the Group in relation to derivative financial instruments used to manage the Group's foreign exchange risks and is recognised in the income statement on the settlement date of the foreign exchange contract.

(f) Other operating expense

Management service fees are recognised in other operating expense on an accruals basis.

(g) Dividends paid and received

Interim dividends received are included in the income statement in the year in which the right to receive the payment is established. Interim dividends paid are deducted from reserves in the year in which they are paid. Final dividends are recorded in the reserves upon shareholder approval. Dividends in specie are recognised at their fair value at the date of receipt.

(h) Finance income and expenses

Finance income and expenses are recognised on an accruals basis using the effective interest method.

(i) Financial assets

Financial assets are measured at amortised cost or fair value through profit or loss. The measurement basis is determined by reference to both the business model for managing the financial asset and the contractual cash flow characteristics of the financial asset.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

2 Summary of significant accounting policies (continued)

(j) Impairment of financial assets

Expected credit losses are recognised in the income statement on financial assets measured at amortised cost.

For financial assets a 12-month expected credit loss ("ECL") allowance is recorded on initial recognition. If there is evidence of a significant increase in the credit risk of an asset, the allowance is increased to reflect the full lifetime ECL. If there is no realistic prospect of recovery, the asset is written off.

(k) Investments in subsidiaries

Investments in subsidiaries are held at cost less accumulated impairment losses.

(l) Impairment of non-current assets

The carrying values of all non-financial assets are reviewed for impairment, either on a standalone basis or as part of a larger cash generating unit, when there is an indication that the assets might be impaired. Any provision for impairment is charged to the income statement in the year concerned.

Impairment losses on non-financial assets are only reversed if there has been a change in estimates used to determine recoverable amounts and only to the extent that the revised recoverable amounts do not exceed the carrying values that would have existed, net of depreciation or amortisation, had no impairments been recognised.

(m) Trade and other receivables

For trade and other receivables, the general approach is used where the Company recognises the losses that are expected to result from all possible default events over the expected life of the receivable when there has been a significant increase in credit risk since initial recognition. However, if the credit risk on the receivable has not increased significantly since initial recognition, the entity measures the expected loss allowance based on losses that are expected to result from default events that are possible within 12 months after the reporting date. When a trade and other receivable is determined to be uncollectable it is written off, firstly against any expected credit loss allowance available and then to the income statement.

Subsequent recoveries of amounts previously provided for are credited to the income statement. Long-term receivables are discounted where the effect is material.

(n) Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, current balances with banks and similar institutions and highly liquid investments with maturities of three months or less. They are readily convertible into known amounts of cash and have an insignificant risk of changes in value.

(o) Trade and other payables

Trade and other payables are initially recognised at fair value and then held at amortised cost using the effective interest method. Long-term payables are discounted where the effect is material.

(p) Taxation

Current tax is provided at the amounts expected to be paid or refunded applying the rates that have been enacted or substantively enacted by the balance sheet date.

Deferred tax is provided in full, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised. Deferred tax is provided on temporary differences arising on investments in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is provided using rates of tax that have been enacted or substantively enacted by the balance sheet date.

(q) Derivative financial instruments and hedging

Derivative financial instruments are used to manage exposure to market risks. The principal derivative instruments used by the Company are foreign exchange forward contracts and swaps, options and interest rate swaps. The Company does not hold or issue derivative financial instruments for trading or speculative purposes.

Derivative financial instruments are classified as held-for-trading and are carried in the balance sheet at fair value. Derivatives designated as hedging instruments are classified on inception as cash flow hedges or fair value hedges.

Changes in the fair value of derivatives designated as cash flow hedges are recognised in other comprehensive income to the extent that the hedges are effective. Ineffective portions are recognised in profit or loss immediately. Amounts deferred in other comprehensive income are reclassified to the income statement when the hedged item affects profit or loss.

Changes in the fair value of derivatives designated as fair value hedges are recorded in the income statement, together with the changes in the fair value of the hedged asset or liability.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

2 Summary of significant accounting policies (continued)

(q) Derivative financial instruments and hedging (continued)

Changes in the fair value of any derivative instruments that do not qualify for hedge accounting are recognised immediately in the income statement.

(r) Share capital

Ordinary shares are classified as equity.

3 Critical accounting judgements

The Directors do not consider that there are any critical accounting judgments that have been made in the process of applying the Company's accounting policies and that have had a significant effect on the amounts recognised in the financial statements.

4 Key sources of estimation uncertainty

In preparing the financial statements, the Directors are required to make estimates and assumptions that affect the amounts of assets, liabilities, revenue and expenses reported in the financial statements. Actual amounts and results could differ from those estimates. The following are considered to be the key accounting estimates and assumptions made.

(a) Impairment of investments in subsidiaries

Investments in subsidiaries are held at cost less accumulated impairment losses. Annual impairment tests are carried out to ascertain if the carrying value of investments are impaired. These tests comprise a comparison between the carrying value of investment in subsidiaries and the net asset value of the subsidiaries. In some instances, the future estimated profit or loss are considered or valuations of subsidiary companies are prepared. Valuations for impairment tests are based on established market multiples or risk-adjusted future cash flows over the estimated useful life of the asset, where limited, discounted using appropriate interest rates.

The assumptions relating to future cash flows, estimated useful lives and discount rates are based on business forecasts and are, therefore, inherently judgemental. Future events could cause the assumptions used in these impairment tests to change with a consequent adverse effect on the future results of the Company.

(b) Impairment of trade receivables

The Company makes an estimate of the expected credit loss of trade and other receivables. When assessing allowance for expected credit losses of trade and other receivables, management considers factors including the credit rating of the receivable, the ageing profile of receivables, historical experience and estimates of future conditions. See Note 16 for the net carrying amount of receivables and associated expected loss allowance (where this is applicable).

5 Financial risk management

Risk management is carried out by the Group's Corporate Treasury under policies and procedures approved annually by the Group's Board of Directors, and most recently on 18 October 2018. The role of Corporate Treasury is to monitor and manage the Group's external and internal funding requirements and financial risks, covering foreign exchange, interest rate, liquidity and credit risks, in support of the Group's strategic objectives. A Treasury Management Group meeting, chaired by the Group's Chief Financial Officer, also takes place on a monthly basis to review treasury activities.

As part of the Group's risk assessment, the potential effects of Brexit have been considered and are not expected to be material.

(a) Market risk

(i) Foreign exchange risk

Foreign currency exposures arise from the translation of financial assets and liabilities which are not in the functional currency of the Company.

The Company is exposed to foreign exchange risk arising from various currency exposures, primarily from the Euro and US dollar. This arises as a result of short-term notes issued under the Group's \$10 billion (£7.9 billion) (2017: \$10 billion (£7.4 billion)) US commercial paper programme and the Group's internal funding requirements predominately made in Euro.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

5 Financial risk management (continued)

(a) Market risk (continued)

(i) Foreign exchange risk (continued)

The Company uses derivative financial instruments to manage the foreign exchange risks arising from these financing activities. These derivatives, principally comprising foreign exchange forward contracts and swaps, are used to swap US commercial paper issuances, intercompany loans and deposits into the Company's functional currency in order to manage the exposure to changes in foreign exchange rates. On this basis, as all of the US commercial paper issuances, intercompany loans and deposits were fully hedged to maturity using foreign exchange forward contracts and swaps, foreign exchange risk is not considered material and the Company has not prepared a sensitivity analysis.

(ii) Interest rate risk

The Group's objective is to minimise the effective net interest cost and to balance the mix of debt at fixed and floating interest rates over time. The policy on interest rate risk management limits the net amount of floating rate debt to a specific cap, reviewed and agreed no less than annually by the GlaxoSmithKline Board.

The Company is exposed to interest rate risk on its outstanding borrowings, investments and the provision of internal funding for the Group issued at floating rates where any changes in interest rates will affect future cash flows. The Company has amounts owed to Group undertakings which are at fixed rates and expose the Company to fair value interest rate risk.

The table below hypothetically shows the Company's sensitivity to changes in interest rates relating to Sterling, US dollar and Euro floating rate financial assets and liabilities. If interest rates applicable to floating rate financial assets were to have increased by 1% (100 basis points), and assuming all other variables had remained constant, it is estimated that the Company's finance income for 2018 would have increased by approximately £242,889,000 (2017: £200,601,000 increase in finance income). A 1% (100 basis points) movement in interest rates is not deemed to have a material effect on equity.

	2018 Increase / (decrease) in income £'000	2017 Increase / (decrease) in income £'000
1% (100 basis points) increase in Sterling interest rates (2017: 1%)	242,887	200,599
1% (100 basis points) increase in US dollar interest rates (2017: 1%)	1	1
1% (100 basis points) increase in Euro interest rates (2017: 1%)	1	1

(b) Credit risk

Credit risk is the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group and arises from cash and cash equivalents and favourable derivative financial instruments held with banks and financial institutions and outstanding trade and other receivables with Group undertakings. Corporate Treasury sets global counterparty limits for each of its banking and investment counterparties based on long-term credit ratings from Standard and Poor's and Moody's Investor Services ("Moody's") and actively manages its exposure to credit risk, reducing surplus cash balances wherever possible. Usage of these limits is monitored daily.

The Company considers its maximum exposure to credit risk at 31 December 2018, without taking into account any collateral held or other credit enhancements, to be £89,401,370,000 (2017: £88,133,994,000) which is the total of the Company's financial assets.

The Company has maintained a conservative approach to counterparty risk throughout the year. The aggregate credit risk in respect of financial assets that the Company may have with one counterparty is limited by reference to the long-term credit ratings assigned for that counterparty by Standard and Poor's and Moody's. The table below sets out the exposure by credit rating category for financial assets held by the Company. The gross asset position on each derivative contract is considered for the purpose of this table, although, under International Swaps and Derivatives Association ("ISDA") agreements, the amount at risk is the net position with each counterparty (Note 7(c) sets out the Company's derivative financial assets and liabilities on an offset basis).

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

5 Financial risk management (continued)

(b) Credit risk (continued)

	AAA/Aaa £'000	AA/Aa £'000	A/A £'000	BBB/Baa and below £'000	Total £'000
2018					
Bank balances and deposits	-	180,223	265,100	-	445,323
Liquidity funds	1,550,325	-	-	-	1,550,325
Third party financial derivatives	-	15,816	125,047	4,348	145,211
Other receivables	-	-	127	50	177
Total	1,550,325	196,039	390,274	4,398	2,141,036
2017					
Bank balances and deposits	-	2,468	71,402	-	73,870
Liquidity funds	393,125	-	-	-	393,125
Third party financial derivatives	-	14,317	30,608	-	44,925
Other receivables	-	-	-	25	25
Total	393,125	16,785	102,010	25	511,945

The credit ratings in the above tables are assigned by Standard and Poor's and Moody's respectively. Where the opinion of the two rating agencies differs, the lower rating of the two is assigned to the counterparty. These credit ratings form the basis of the assessment of the expected credit loss on balances held at amortised cost consisting of bank balances and deposits and other receivables.

Expected credit losses over cash and cash equivalents is measured as a function of individual counterparty credit ratings and associated 12 month default rates. Expected credit losses over cash and cash equivalents and third party financial derivatives are deemed to be immaterial and no such loss had been experienced during 2018.

The Company's greatest concentration of credit risk was in liquidity funds of £400,102,000 with LGIM (AAA/Aaa) (2017: liquidity funds of £120,519,000 with HSBC Bank (AAA/Aaa)).

Amounts owed by Group undertakings of £97,260,335,000 (2017: £87,622,050,000) has not been disclosed in the above table as these entities are all indirectly owned by GlaxoSmithKline plc whose long-term credit rating with Standard and Poor's is "A+" (negative outlook) and with Moody's is "A2" (negative outlook).

There are no financial assets that are past due or impaired as at 31 December 2018 (2017: £nil).

The Company did not hold any collateral as security or obtained other credit enhancements as at 31 December 2018 (2017: £nil).

(c) Liquidity risk

Liquidity is managed centrally by the Group by borrowing in order to meet anticipated funding requirements and to diversify liquidity sources using a range of facilities and to maintain broad access to financial markets. Group cash flow forecast and funding requirements are monitored regularly by the Treasury Management Group and the strategy is to have diversified liquidity sources using a range of facilities and to maintain broad access to funding markets.

6 Capital management

GlaxoSmithKline's financial strategy supports the Group's strategic priorities and is regularly reviewed by the Board, of which the capital structure of the Group is managed through an appropriate mix of debt and equity.

The capital structure of the Company consists of total equity of £53,903,449,000 (2017: £61,286,526,000), see Statement of changes in equity.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

7 Financial instruments

(a) Fair value of financial assets and liabilities

The fair values of the financial assets and liabilities are included at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The following methods and assumptions were used to estimate the fair values:

- Cash and cash equivalents – approximates to the carrying amount;
- Liquid investments – approximates to the carrying amount;
- Short-term borrowings, overdrafts and commercial paper – approximates to the carrying amount because of the short maturity of these instruments;
- Interest rate swaps, foreign exchange forward contracts and swaps – based on the present value of contractual cash flows using market sourced data (exchange rates) at the balance sheet date;
- Long-term borrowings with Group undertakings – approximates to the fair value of borrowings (European and US Medium Term Notes by GlaxoSmithKline Capital plc which is on lent to the Company) based on quoted market prices; and
- Receivables and payables – approximates to the carrying amount.

The carrying amounts and the fair values of the Company's financial assets and liabilities at 31 December 2018 and 31 December 2017 are illustrated below.

	Carrying value £'000	2018 Fair value £'000	Carrying value £'000	2017 Fair value £'000
Cash and cash equivalents	1,995,323	1,995,323	466,914	466,914
Trade and other receivables:				
Amounts owed by Group undertakings:				
Due within one year	83,999,883	83,999,883	86,114,168	86,114,168
Due after more than one year	3,070,430	3,131,368	1,464,741	1,502,667
Other receivables due after more than one year	50	50	25	25
Prepayments and accrued income	18,516	18,516	7,475	7,475
	87,088,879	87,149,817	87,586,409	87,624,335
Financial assets at fair value through profit or loss:				
Derivatives designated as at fair value through profit or loss	-	-	8	8
Derivatives classified as held for trading	317,168	317,168	80,663	80,663
	317,168	317,168	80,671	80,671
Total financial assets	89,401,370	89,462,308	88,133,994	88,171,920
Financial liabilities measured at amortised cost:				
Bank overdrafts	(12,297)	(12,297)	(1,404)	(1,404)
Amounts owed to Group undertakings:				
Due within one year	(74,125,977)	(74,125,977)	(67,340,486)	(67,340,486)
Due after more than one year	(7,802,372)	(9,305,375)	(6,130,327)	(8,008,059)
	(81,940,646)	(83,443,649)	(73,472,217)	(75,349,949)
Other payables	(143,812)	(143,812)	(135,830)	(135,830)
Financial liabilities at fair value through profit or loss:				
Derivatives classified as held for trading	(193,176)	(193,176)	(83,303)	(83,303)
Total financial liabilities	(82,277,634)	(83,780,637)	(73,691,350)	(75,569,082)
Net financial assets	7,123,736	5,681,671	14,442,644	12,602,838

Loans with Group undertakings include the net proceeds of bond issuances by GlaxoSmithKline Capital plc that have been advanced as loans to the Company and are measured at amortised cost, of which the fair value is disclosed in the table above. These are categorised as Level 1, where quoted prices in active markets are used.

Financial assets and liabilities at fair value through profit or loss are derivative financial instruments categorised as Level 2, where the fair value is determined using valuation techniques that are based on observable market sourced data (exchange rates). All other financial assets and liabilities approximate to the carrying amount.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

7 Financial instruments (continued)

(b) Contractual cash flows for non-derivative financial liabilities and derivative instruments

The following tables provide an analysis of the anticipated contractual cash flows including interest payable for the Company's non-derivative financial liabilities on an undiscounted basis. For the purpose of this table, debt is defined as all classes of borrowings. Interest is calculated based on debt held at 31 December without taking account of future borrowings. Floating rate interest is estimated using the prevailing interest rate at the balance sheet date. Cash flows in foreign currencies are translated using spot rates at 31 December.

	At 31 December 2018		At 31 December 2017	
	Debt	Interest on debt	Debt	Interest on debt
	£'000	£'000	£'000	£'000
Due in less than one year	(74,129,417)	(379,027)	(67,341,890)	(286,278)
Between one and two years	-	(355,370)	-	(282,529)
Between two and three years	-	(320,424)	-	(282,531)
Between three and four years	(1,568,219)	(261,822)	-	(282,529)
Between four and five years	(1,557,008)	(237,766)	(1,464,741)	(259,900)
Between five and ten years	(1,243,241)	(1,082,626)	(1,231,682)	(1,131,174)
Greater than ten years	(3,433,904)	(2,112,300)	(3,433,904)	(2,300,028)
Gross contractual cash flows	(81,931,789)	(4,749,335)	(73,472,217)	(4,824,969)

The table below provides an analysis of the anticipated contractual cash flows for the Company's derivative instruments using undiscounted cash flows. Cash flows in foreign currencies are translated using spot rates at 31 December. The gross cash flows of foreign exchange contracts are presented for the purposes of this table although, in practice, the Company uses standard settlement arrangements to reduce its liquidity requirements on these instruments.

	Receivables		Payables	
	Interest rate swaps	Foreign exchange forward contracts and swaps	Interest rate swaps	Foreign exchange forward contracts and swaps
	£'000	£'000	£'000	£'000
2018				
Due in less than one year	48,905	55,629,071	(3,155)	(55,815,030)
Between one and two years	48,222	-	(3,162)	-
Between two and three years	23,538	1,574,803	(2,443)	(1,513,422)
Gross contractual cash flows	120,665	57,203,874	(8,760)	(57,328,452)

	Receivables		Payables	
	Interest rate swaps	Foreign exchange forward contracts and swaps	Interest rate swaps	Foreign exchange forward contracts and swaps
	£'000	£'000	£'000	£'000
2017				
Due in less than one year	-	29,290,406	-	(29,434,485)
Between one and two years	-	-	-	-
Between two and three years	-	-	-	-
Gross contractual cash flows	-	29,290,406	-	(29,434,485)

(c) Offsetting of financial assets and liabilities

Financial assets and liabilities are offset and the net amount reported in the balance sheet where there is a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. There are also arrangements that do not meet the criteria for offsetting but still allow for the related amounts to be set off in certain circumstances, such as bankruptcy or the termination of a contract.

The following tables set out the financial assets and liabilities that are offset, or subject to enforceable master netting arrangements and other similar agreements but not offset, as at 31 December 2018 and 31 December 2017. The column "net" shows the impact on the Company's balance sheet if all set-off rights were exercised.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

7 Financial instruments (continued)

(c) Offsetting of financial assets and liabilities (continued)

	Gross financial assets / (liabilities) £'000	Financial assets / (liabilities) offset £'000	Net financial assets / (liabilities) £'000	Related amounts not offset £'000	Net £'000
2018					
Derivative financial assets	317,168	-	317,168	(86,301)	230,867
Derivative financial liabilities	(193,176)	-	(193,176)	86,301	(106,875)
	Gross financial assets / (liabilities) £'000	Financial assets / (liabilities) offset £'000	Net financial assets / (liabilities) £'000	Related amounts not offset £'000	Net £'000
2017					
Derivative financial assets	80,671	-	80,671	(52,380)	28,291
Derivative financial liabilities	(83,303)	-	(83,303)	52,380	(30,923)

Amounts which do not meet the criteria for offsetting on the balance sheet but could be settled net in certain circumstances principally relate to derivative transactions under ISDA agreements where each party has the option to settle amounts on a net basis in the event of default of the other party. As there is presently not a legally enforceable right of set-off, these amounts have not been offset in the balance sheet, but have been presented separately in the table above.

8 Turnover

Turnover of £69,119,000 (2017: £84,262,000) is not analysed by segment because the Company operates within one business sector (finance sector) and geographical sector (United Kingdom).

9 Employees

All UK employees are remunerated by GlaxoSmithKline Services Unlimited and receive no remuneration from the Company. A management fee is charged by GlaxoSmithKline Services Unlimited for services provided to the Company (see Note 12). The Company has no employees (2017: nil).

10 Finance income

	2018 £'000	2017 £'000
Finance income arising from:		
Financial assets measured at amortised cost	716,719	535,617
Financial assets measured at fair value through profit or loss	19,840	23,894
Net gains arising from financial instruments at fair value through profit or loss	61,092	-
Total finance income	797,651	559,511

Interest income arising from financial assets measured at amortised cost includes interest income arising amounts owed by Group undertakings of £713,066,000 (2017: £534,819,000) and bank balances and deposits of £3,653,000 (2017: £798,000). Interest income arising from financial assets measured at fair value through profit or loss includes interest income arising from investments in money market funds of £6,058,000 (2017: £758,000).

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

11 Finance expenses

	2018 £'000	2017 £'000
Finance expense arising on:		
Financial liabilities measured at amortised cost	(496,835)	(352,230)
Financial liabilities measured at fair value through profit or loss	(91,816)	(57,377)
Net losses arising from:		
Financial instruments at fair value through profit or loss	(70,012)	(62,828)
Reclassification of hedges from other comprehensive income	(9)	(508)
Total finance expenses	(658,672)	(472,943)

Interest expense arising from financial liabilities measured at amortised cost includes interest expense arising from amounts owed to Group undertakings of £564,717,000 (2017: £351,171,000), bank overdrafts and commercial paper of £2,130,000 (2017: £1,059,000). Investments in money market funds, included in cash and cash equivalents, are classified as fair value through profit or loss. Due to the prevailing economic conditions in the Eurozone, the yields on these liquidity funds were negative over the year, giving rise to an interest expense of £434,000 (2017: £308,000).

12 Operating profit

	2018 £'000	2017 £'000
The following items have been credited / (charged) in operating profit:		
Exchange gains on foreign currency transactions	302,763	-
Management fee	(8,857)	(8,196)

On 1 June 2018, the Group completed the transaction with Novartis AG ("Novartis") to buy out Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for \$13 billion (£9.2 billion). The Company used derivative financial instruments to manage the Group's foreign exchange risk arising from this transaction generating a gain of £302,763,000 (2017: £nil).

GlaxoSmithKline Services Unlimited provides various services and facilities to the Company for which a management fee was charged of £8,857,000 (2017: £8,196,000). Included in the management fee is an audit fee of £13,800 (2017: £13,249). The disclosure of fees payable to the auditor and its associates for other (non-audit) services has not been made and has been disclosed in the Group's 2018 Annual Report which does not form part of this report. The Company did not incur any non-audit service fees during the financial year.

13 Income from subsidiaries

	2018 £'000	2017 £'000
Dividends from subsidiaries	2,210,107	10,000,000

The Company received a dividend from GlaxoSmithKline Holdings (America) Inc of £2,210,107,000 (US\$3,000,000,000) on 4 May 2018 (2017: £5,000,000,000 from Glaxo Group Limited and £5,000,000,000 from Setfirst Limited).

14 Taxation

	2018 £'000	2017 £'000
Income tax charge on profit		
Current tax:		
UK corporation tax at 19.00% (2017: 19.25%)	(96,483)	(32,395)
Double tax relief	9	3
Overseas tax	(9)	(3)
Adjustments in respect of previous years	1,157	1,143
Total current tax	(95,326)	(31,252)
Deferred tax:		
Origination and reversal of timing differences	(92)	(92)
Total deferred tax	(92)	(92)
Total tax charge for the year	(95,418)	(31,344)

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

14 Taxation (continued)

The tax assessed for the year is lower (2017: lower) than the standard rate of corporation tax in the UK for the year ended 31 December 2018 of 19.00% (2017: 19.25%). The differences are explained below:

	2018 £'000	2017 £'000
Reconciliation of total tax charge		
Profit on ordinary activities before tax	2,712,362	10,166,165
Profit on ordinary activities at the UK standard rate 19.00% (2017: 19.25%)	(515,349)	(1,956,639)
Effects of:		
Overseas tax	(9)	(3)
Double tax relief	9	3
Income not taxable	419,920	1,925,296
Change in tax rate - impact on deferred tax	11	12
Adjustments to tax charge in respect of previous years	1,157	1,143
Other differences	(1,157)	(1,156)
Total tax charge for the year	(95,418)	(31,344)

Factors that may affect future tax charges:

A reduction in the UK corporation tax rate from 20% to 19% (effective from 1 April 2017) was substantively enacted on 26 October 2015, and a further reduction to 17% (effective 1 April 2020) was substantively enacted on 6 September 2016. This will reduce the company's future current tax charge accordingly. The deferred tax asset at 31 December 2018 has been calculated based on these rates.

	2018 £'000	2017 £'000
Tax credit included in other comprehensive income		
Deferred tax:		
Fair value movements on cash flow hedges	4	409
Total tax expense in other comprehensive income	4	409

Movement in deferred tax asset

	Other net temporary differences £'000	Total £'000
At 1 January 2017	324	324
Charge to income statement	(92)	(92)
Credit to other comprehensive income	409	409
At 31 December 2017	641	641
At 1 January 2018	641	641
Charge to income statement	(92)	(92)
Credit to other comprehensive income	4	4
At 31 December 2018	553	553

After offsetting deferred tax assets and liabilities where appropriate, the net deferred tax asset comprises:

	2018 £'000	2017 £'000
Deferred tax assets classified as non-current assets	553	641

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

15 Investments in subsidiaries

Cost	Shares at cost £'000	Total £'000
At 1 January 2017	46,875,633	46,875,633
At 31 December 2017	46,875,633	46,875,633
At 31 December 2018	46,875,633	46,875,633
Carrying value at 1 January 2017	46,875,633	46,875,633
Carrying value at 31 December 2017	46,875,633	46,875,633
Carrying value at 31 December 2018	46,875,633	46,875,633

Details of the subsidiary undertakings both directly and indirectly owned by the Company as at 31 December 2018 are disclosed in Note 29.

The Directors believe that the carrying value of the investments are supported by their underlying net assets.

16 Trade and other receivables

	2018 £'000	2017 £'000
Amounts due within one year		
Amounts owed by Group undertakings	83,999,883	86,114,168
	83,999,883	86,114,168
Amounts due after more than one year		
Amounts owed by Group undertakings	3,070,430	1,464,741
Other receivables	50	25
	3,070,480	1,464,766
	87,070,363	87,578,934

Amounts due within one year consist of short-term loans denominated in various currencies with Group undertakings which are unsecured, repayable on demand and earn a market effective rate of interest (based on benchmark LIBOR applicable to each currency plus 0.25%) of 1.37% (2017: 0.73%) that is consistent with the Group's policy and call accounts with Group undertakings denominated in Pounds Sterling that are unsecured, repayable on demand and earn a market rate of interest (based on LIBOR plus 0.25%) of 0.73% (2017: 0.73%) that is consistent with the Group's policy.

Amounts due after more than one year are unsecured loans to GlaxoSmithKline Holdings (Americas) Inc. earning fixed interest of 3.19% per annum and repayable at maturity in 2022 and Setfirst Limited earning fixed interest at 0.41% per annum and repayable at maturity in 2021.

Other receivables relate to funds deposited with SecurMed UK earning fixed interest at 2.00% per annum and repayable at maturity in 2020.

17 Trade and other payables

	2018 £'000	2017 £'000
Amounts falling due within one year		
Amounts owed to Group undertakings	(74,125,977)	(67,340,486)
Corporation tax	(96,473)	(32,392)
	(74,222,450)	(67,372,878)

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

17 Trade and other payables (continued)

Amounts falling due within one year are balances denominated in various currencies with Group undertakings which are unsecured, repayable on demand and incur a market effective rate of interest (based on benchmark LIBOR applicable to each currency minus 0.25%) of 0.40% (2017: 0.28%) that is consistent with the Group's policy and call accounts with Group undertakings denominated in Pounds Sterling that are unsecured, repayable on demand and incur a market rate of interest (based on LIBOR minus 0.25%) of 0.73% (2017: 0.36%) that is consistent with the Group's policy. In addition, there is an amount of £28,000 (2017: £27,000) that is owed to Group undertakings and is unsecured and repayable on demand.

The corporation tax creditor contains amounts which will be paid to fellow Group undertakings under Group relief.

18 Prepayments and accrued income

	2018 £'000	2017 £'000
Amounts falling due within one year		
Accrued income	451	81
Amounts owed by Group undertakings	18,065	7,394
	18,516	7,475

Accrued income relates to interest on cash and cash equivalents (Note 20).

Amounts owed by Group undertakings represent interest receivable on amounts owed by Group undertakings (see Note 16).

19 Derivative financial instruments

Derivatives are only used for economic hedging purposes and not as speculative investments and are classified as "held for trading", other than designated and effective hedging instruments, and are presented as current assets or liabilities if they are expected to be settled within 12 months after the end of the reporting period, otherwise they are classified as non-current.

The Company has the following derivative financial instruments:

	2018		2017	
	Assets £'000	Liabilities £'000	Assets £'000	Liabilities £'000
Current				
Cash flow hedges – Foreign exchange forward contracts and swaps (principal amount - £nil (2017: £8,850,000))	-	-	8	-
Derivatives designated and effective as hedging instruments	-	-	8	-
Non-current				
Interest rate swaps (principal amount - £3,500,000,000 (2017: £nil) and average contracted fixed rate of 0.14% (2017: nil%)).	65,642	(1,151)	-	-
Current				
Foreign exchange forward contracts and swaps (principal amount - £42,497,729,000 (2017: £16,420,247,000))	251,526	(192,025)	80,663	(83,303)
Derivatives classified as held for trading	317,168	(193,176)	80,663	(83,303)
Total derivative instruments	317,168	(193,176)	80,671	(83,303)

During 2018, the Company had no derivatives designated and effective as hedging instruments.

These derivative financial instruments are used to mitigate exposure to foreign exchange transactional risks. The derivative financial instruments are measured at fair value, which is determined using valuation techniques that utilise observable inputs. The valuations of derivative financial instruments are based on the present value of net contractual cash flows using market sourced data (exchange rates).

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

20 Cash and cash equivalents

	2018 £'000	2017 £'000
Bank balances and deposits	445,323	73,868
Liquidity funds	1,550,000	393,046
	1,995,323	466,914

21 Borrowings

	2018 £'000	2017 £'000
Amounts falling due within one year		
Bank overdrafts	(12,297)	(1,404)
	(12,297)	(1,404)
Amounts falling due after more than one year		
Amounts owed to Group undertakings	(7,802,372)	(6,130,327)
	(7,802,372)	(6,130,327)
Total borrowings	(7,814,669)	(6,131,731)

Amounts due after more than one year are unsecured loans with GlaxoSmithKline Capital plc and repayable at their stated maturity. A maturity analysis of these amounts is provided in the table below.

	2018 £'000	2017 £'000
In more than two years, but not more than five years		
3.42% US\$ Loan Notes 2021	(979,144)	-
2.69% US\$ Loan Notes 2021	(589,075)	-
3.09% US\$ Loan Notes 2022	(1,557,008)	(1,464,741)
	(3,125,227)	(1,464,741)
In more than five years		
4.30% € Loan Notes 2025	(653,123)	(641,564)
3.72% £ Loan Notes 2027	(590,118)	(590,118)
5.56% £ Loan Notes 2033	(972,810)	(972,810)
6.50% £ Loan Notes 2039	(693,161)	(693,161)
5.45% £ Loan Notes 2042	(980,405)	(980,405)
4.47% £ Loan Notes 2045	(787,528)	(787,528)
	(4,677,145)	(4,665,586)
	(7,802,372)	(6,130,327)

The fair value of current borrowings equals their carrying amount as the impact of discounting is not significant.

22 Accruals and deferred income

	2018 £'000	2017 £'000
Amounts falling due within one year	(143,812)	(135,830)

Amounts falling due within one year relates to interest payable on amounts owed to Group undertakings (see Note 17) of £141,881,000 (2017: £135,830,000) and deferred income of £1,931,000 (2017: £nil) arising from the interest rate swap contracts used to manage the Group's interest rate risk arising from the buy out of Novartis' 36.5% stake in their Consumer Healthcare Joint Venture for \$13 billion (£9.2 billion).

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

23 Called up share capital

	2018 Number of shares	2017 Number of shares	2018 £'000	2017 £'000
Authorised				
Ordinary shares of £1 each (2017: £1 each)	20,300,000,000	20,300,000,000	20,300,000	20,300,000
Issued and fully paid				
Ordinary shares of £1 each (2017: £1 each)	17,870,000,000	17,870,000,000	17,870,000	17,870,000

24 Dividends paid

	Pence per share	£'000
Dividends paid in 2018		
21 June 2018 - interim dividend paid	55.96	10,000,000
Dividends paid in 2017		
27 June 2017 - interim dividend paid	55.96	10,000,000

The Company declared and paid a dividend of £10,000,000,000 on 21 June 2018 GlaxoSmithKline Holdings Limited in respect of the financial year ended 31 December 2017 (2017: £10,000,000,000, declared and paid to GlaxoSmithKline Holdings Limited on 27 June 2017 in respect of the financial year ended 31 December 2016).

25 Contingent liabilities/assets

Group banking arrangement

The Company, together with fellow Group undertakings has entered into a Group banking arrangement with the Company's principal bank. The bank holds the right to pay and apply funds from any account of the Company to settle any indebtedness to the bank of any other party to this agreement. The Company's maximum potential liability as at 31 December 2018 is limited to the amount held on its accounts with the bank. No loss is expected to accrue to the Company from the agreement.

26 Directors' remuneration

During the year, the Directors of the Company, with the exception of the Corporate Directors, were remunerated as executives of the Group and received no remuneration in respect of their services to the Company (2017: £nil). Corporate Directors received no remuneration during the year, either as executives of the Group or in respect of their services to the Company (2017: £nil).

27 Related party transactions

As a wholly owned subsidiary of the ultimate parent company, GlaxoSmithKline plc, advantage has been taken of the exemption afforded by FRS 101 Reduced Disclosure Framework not to disclose any related party transactions with other wholly owned members of the Group, or information around remuneration of key management personnel compensation. Details of other material related party transactions are disclosed below.

	2018 £'000	2017 £'000
Sterling call account due to GlaxoSmithKline Consumer Healthcare Finance Limited	(83)	382,850

GlaxoSmithKline Consumer Healthcare Finance Limited is wholly owned by GlaxoSmithKline Consumer Healthcare Holdings Limited.

The call account is unsecured, repayable by either party on demand, earning interest income at LIBOR plus 0.25% on end of day receivable balances and incurring interest expense at LIBOR minus 0.125% on end of day payable balances. For the year ended 31 December 2018, interest income was £360,000 (2017: £354,000) and interest expense was £443,000 (2017: £197,000).

28 Events after the end of the reporting period

On 23 May 2019, GlaxoSmithKline Holdings Limited undertook a share for share exchange whereby it subscribed for one ordinary share in the Company of £1 at a share premium of £8.9 billion in consideration for the transfer of US\$11.5 billion of its preference shares in Setfirst Limited to the Company. The US\$11.5 billion preference shares were redenominated to GBP preference shares and subdivided into shares with a nominal value of £1 each. These preference shares held by the Company in Setfirst Limited were redesignated as GBP ordinary shares and eliminated via capital reduction.

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings

The subsidiaries of the Company as at 31 December 2018 are as follows:

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
1506369 Alberta ULC	Common		100	3500 855-2nd Street SW, Calgary, AB, T2P 4J8, Canada
Action Potential Venture Capital Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Adechsa GmbH	Ordinary		100	c/o PRV Provides Treuhandgesellschaft AG, Dorfstrasse 38, Baar, 6341, Switzerland
Adriatic Acquisition Corporation	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Affymax Research Institute	Common		100	Corporation Service Company, 2710 Gateway Oaks Drive, Suite 150N, Sacramento, California, 95833, United States
Alenfarma - Especialidades Farmaceuticas, Limitada	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal
Allen & Hanburys Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Allen & Hanburys Pharmaceutical Nigeria Limited	Ordinary		100	24 Abimbola Way, Ilasamaja, Isolo, Lagos, Nigeria
Allen Farmaceutica, S.A.			100	Severo Ochoa, 2, Parque Tecnologico de Madrid, Tres Cantos, Madrid, 28760, Spain
Allen Pharmazeutika Gesellschaft m.b.H.	Ordinary		100	Wagenseilgasse 3, Euro Plaza, Gebäude I, 4. Stock, Vienna, A-1120, Austria
Barrier Therapeutics, Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
BEECHAM GROUP p.l.c	20p Shares "A"; 5p Shares "B"		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Beecham Pharmaceuticals (Pte) Limited	Ordinary		100	38 Quality Road, Jurong Industrial Estate, Jurong, 618809, Singapore
Beecham Pharmaceuticals S.A.	Nominative		100	Av 10 De Agosto N36-239, y Naciones Unidas, Edificio Electroelectoriana, 2do piso, Quito, Ecuador
Beecham Portuguesa-Produtos Farmaceuticos e Quimicos, Lda, Beecham S.A.	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal
	Ordinary		100	Parc de la Noire Epine, rue Fleming 20, 1300 Wavre, Belgium
Biovesta İlaçları Ltd. Sti.	Nominative		100	Büyükdere Caddesi No. 173, 1.Levent Plaza B Blok, 1.Levent, Istanbul, 34394, Turkey
Block Drug Company, Inc.	Common		100	Corporation Service Company, Princeton South Corporate Center, Suite 160, 100 Charles Ewing Blvd, Ewing, New Jersey, 08628, United States
Block Drug Corporation	Common		100	Corporation Service Company, Princeton South Corporate Center, Suite 160, 100 Charles Ewing Blvd, Ewing, New Jersey, 08628, United States
Burroughs Wellcome & Co (Bangladesh) Limited	Ordinary		100	Fouzderhat Industrial Area, Dhaka Trunk Road, North Kattali, Chittagong - 4217, Bangladesh
Burroughs Wellcome International Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Cascan GmbH & Co. KG	Partnership Capital		100	Industriestrasse 32-36, Bad Oldesloe, 23843, Germany
Castleton Investment Ltd	Ordinary		100	C/O DTOS, 19 Cybercity, 10th Floor Standard Chartered Tower, Ebene, Mauritius
Cellzome GmbH	Ordinary		100	Meyershofstrasse 1, Heidelberg, 69117, Germany
Cellzome Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Cellzome Therapeutics, Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Cellzome, Inc.	Common; Series A Preferred; Series B Preferred; Series C-1 Convertible Preferred; Series C-3 Convertible Preferred		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Charles Midgley Limited	Ordinary; 7% Cumulative Preference		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Chiron Behring Vaccines Private Limited	Ordinary		100	401-402, A, Wing, 4th Floor, Floral Deck Plaza, Opp Rolta Bhavan, Central MIDC Road, Mumbai, Andheri (E), 400093, India
Clarges Pharmaceuticals Limited	Ordinary; Preference (99.97%)		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Colleen Corporation	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
Corixa Corporation	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Coultter Pharmaceutical, Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
de Miclén a.s.	Ordinary		100	Priemyselny Park Gena, Ul. E. Sachsa 4-6, 934 01, Levice, Slovakia
Dealcyber Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Desarrollo Energia Solar Alternativa S.L.	Ordinary		100	Severo Ochoa, 2, Parque Tecnológico de Madrid, Tres Cantos, Madrid, 28760, Spain
Domantis Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Duncan Consumer Healthcare Philippines Inc	Common		100	2266 Don Chino Rocas Avenue, Makati City, Philippines
Duncan Flockhart Australia Pty Limited	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
Duncan Pharmaceuticals Philippines Inc.	Common		100	2266 Chino Rocas Avenue, City of Makati, 1231, Philippines
Edinburgh Pharmaceutical Industries Limited	Ordinary; Preference		100	Shewalton Road, Irvine, Ayrshire, KA11 5AP, Scotland
Eskaylab Limited	10p Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Etex Farmaceutica Ltda	Social Capital		100	Avenue Andres Bello 2687, Piso 19, Las Condes, Santiago, C.P. 7550611, Chile
Ex-Lax, Inc.	Common		100	The Prentice Hall Corporation System, Puerto Rico, Inc., c/o Fast Solutions, LLC, Citi Tower, 252 Ponce de Leon Avenue, Floor 20, San Juan, 00918, Puerto Rico
Fipar (Thailand) Ltd	Ordinary		100	12th Floor Wave Place, 55 Wireless Road, Lumpini, Pathumwan, Bangkok, 10330, Thailand
Genelabs Technologies, Inc.	Common		100	Corporation Service Company, 2710 Gateway Oaks Drive, Suite 150N, Sacramento, California, CA, 95833, United States
Glaxo AS	Ordinary		100	Drammensveien 288, 1326 Lysaker, Norway
Glaxo Group Limited	Ordinary	100		980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Glaxo Kabushiki Kaisha	Ordinary		100	1-8-1 Akasaka Minato-Ku, Tokyo, Japan
Glaxo Laboratories (Nigeria) Limited	Ordinary		100	82 Marine Road, Apapa, Lagos, Nigeria
Glaxo Laboratories Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Glaxo New Zealand Pension Plan Trustee Limited	Ordinary		100	Level 11, Zurich House, 21 Queen Street, Auckland, 1010, New Zealand
Glaxo Operations UK Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Glaxo Properties BV	Ordinary		100	Huis ter Heideweg 62, 3705 LZ, Zeist, Netherlands
Glaxo Verwaltungs GmbH	Ordinary		100	Industriestrasse 32-36, Bad Odesloe, 23843, Germany
Glaxo Wellcome Australia Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
Glaxo Wellcome Farmaceutica, Limitada	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal
Glaxo Wellcome International B.V.	Ordinary		100	Huis ter Heideweg 62, 3705 LZ, Zeist, Netherlands
Glaxo Wellcome Manufacturing Pte Ltd	Ordinary		100	1 Pioneer Sector 1, Jurong Industrial Estate, Jurong, 628413, Singapore
Glaxo Wellcome Production S.A.S.	Ordinary		100	23 rue François Jacob, 92500, Rueil-Malmaison, France
Glaxo Wellcome UK Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Glaxo Wellcome Vidhyasom Limited	Ordinary		100	12th Floor Wave Place, 55 Wireless Road, Lumpini, Pathumwan, Bangkok, 10330, Thailand
Glaxo Wellcome, S.A.	Ordinary		100	Poligono Industrial Allenduedero, Avenida de Extremadura, 3, Aranda de Duero, Burgos, 09400, Spain
Glaxo, S.A.	Ordinary		100	Severo Ochoa, 2, Parque Tecnológico de Madrid, Tres Cantos, Madrid, 28760, Spain
Glaxo-Allenburys (Nigeria) Limited	Ordinary		100	41 Creek Road, Apapa, Lagos, PMB 1401, Nigeria
Glaxochem (UK) Unlimited	Ordinary; Ordinary B; Ordinary C		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Glaxochem Pte Ltd	Ordinary		100	23 Rochester Park, 139234, Singapore
GlaxoSmithKline - Produtos Farmaceuticos, Limitada	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal
GlaxoSmithKline (Cambodia) Co., Ltd.	Ordinary		100	5th Floor DKSH Building, No.797 Preah Monivong Boulevard (Corner of Street 484), Sangkat Phsar Deum Thakov, Khan Chamkarmon, Phnom Penh, Cambodia
GlaxoSmithKline (China) Investment Co Ltd	Ordinary		100	Room 901 - 910, Building A, Ocean International Center, 56 Mid 4th East Ring Road, Beijing, Chaoyang District, China
GlaxoSmithKline (China) R&D Company Limited	Equity		100	No 3 Building, 898 Halei Road, Zhang Jiang, Hi Tech Park Pudong New Area, Shanghai, China

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
GlaxoSmithKline (Cyprus) Limited	Ordinary		100	Arch. Makariou III, 2-4, Capital Center, 9th Floor, Nicosia, P.C. 1505, Cyprus
GlaxoSmithKline (GSK) S.R.L.	Ordinary		100	1-5 Costache Negri Street, Opera Center One, 5th and 6th floors, Zone 1, District 5, Bucharest, Romania
GlaxoSmithKline (Ireland) Limited	Ordinary		100	12 Riverwalk Citywest Business Campus, Dublin, 24, Ireland
GlaxoSmithKline (Israel) Ltd	Ordinary		100	25 Basel Street, PO Box 10283, Petach-Tikva, 49002, Israel
GlaxoSmithKline (Malta) Limited	Ordinary		100	1, First Floor, De La Cruz Avenue, Qormi, QRM2458, Malta
GlaxoSmithKline (Private) Limited	Ordinary		100	Unit 3, 20 Anthony Road, Msasa, Harare, Zimbabwe
GlaxoSmithKline (Thailand) Limited	Ordinary		100	12th Floor Wave Place, 55 Wireless Road, Lumpini, Pathumwan, Bangkok, 10330, Thailand
GlaxoSmithKline A.E.B.E.	Ordinary		100	266 Kifissias Avenue, Halandri, Athens, 152 32, Greece
GlaxoSmithKline AB	Ordinary		100	Hemvarmsg. 9, Solna, 171 54, Sweden
GlaxoSmithKline AG	Ordinary		100	Talstrasse 3-5, 3053 Muenchenbuchsee, Switzerland
GlaxoSmithKline Angola Unipessoal Limitada	Quotas		100	Luanda, Bairro Petrangol, Estrada de Cacuaco n ° 288, Angola
GlaxoSmithKline Argentina S.A.	Ordinary		100	Tucumán 1, piso 4, Buenos Aires, C1049AAA, Argentina
GlaxoSmithKline AS	Ordinary		100	Drammensveien 288, 1326 Lysaker, Norway
GlaxoSmithKline Asia Pvt. Limited	Equity		100	Patiala Road, Nabha 147201, Dist Patiala, Punjab, India
GlaxoSmithKline Australia Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
GlaxoSmithKline B.V.	Ordinary		100	Huis ter Heideweg 62, 3705 LZ, Zeist, Netherlands
GlaxoSmithKline Beteiligungs GmbH	Ordinary		100	Prinzregentenplatz 9, Munchen, 81675, Germany
GlaxoSmithKline Biologicals (Shanghai) Ltd.	Ordinary		100	No. 277 Niudun Road, China (Shanghai) Pilot Free Trade Zone
GlaxoSmithKline Biologicals Kft.	Ordinary		100	2100 Gödöllő, Homoki Nagy István utca 1, Hungary
GlaxoSmithKline Biologicals S.A.S.	Ordinary		100	637 Rue des Aulnois, Saint-Amand Les Eaux, 59230, France
GlaxoSmithKline Biologicals SA	Ordinary; Preference		100	Rue de l'Institut 89, B-1330 Rixensart, Belgium
GlaxoSmithKline Brasil Limitada	Quotas		100	Estrada dos Banderiantes, 8464, Rio de Janeiro, 22783-110, Brazil
GlaxoSmithKline Brasil Produtos para Consumo e Saude Ltda	Quotas		100	66 BL1/302, Vitor Civita Street, Barra Tijuca, Rio de Janeiro, 22775-044, Brazil
GlaxoSmithKline Capital Inc.	Common		100	Wilmington Trust SP Services Inc., 1105 North Market Street, Suite 1300, Wilmington, Delaware, 19801, United States
GlaxoSmithKline Capital plc	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Caribbean Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Chile Farmaceutica Limitada	Social Capital		100	Avenue Andres Bello No. 2687, Piso 19, Las Condes, Santiago, C.P. 7550611, Chile
GlaxoSmithKline Colombia S.A.	Ordinary		100	Avenida El Dorado, #69B-45/Piso 9, Bogota, Colombia
GlaxoSmithKline Consumer Healthcare (China) Co. Ltd	Ordinary		100	Floor 8, 168 Xizangzhong Road, Huangpu District, Shanghai, China
GlaxoSmithKline Consumer Healthcare (Hong Kong) Limited	Ordinary		100	Units 2201, 2214 and 23/F, Tower 6, The Gateway, 9 Canton Road, Harbour City, Tsimshatsui, Kowloon, Hong Kong
GlaxoSmithKline Consumer Healthcare (Ireland) Limited	Ordinary		100	12 Riverwalk Citywest Business Campus, Dublin, 24, Ireland
GlaxoSmithKline Consumer Healthcare (Overseas) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Consumer Healthcare (Thailand) Limited	Ordinary		100	13th Floor, Unit 13.05 and 13.06 Wave Place, 55 Wireless Road, Lumpini, Pathumwan, Bangkok, 10330, Thailand
GlaxoSmithKline Consumer Healthcare (UK) (No.1) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Consumer Healthcare (UK) IP Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Consumer Healthcare (US) LLC Interests	LLC Interests		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GlaxoSmithKline Consumer Healthcare A/S	Ordinary		100	Nykaer 68, Brøndby, DK-2605, Denmark
GlaxoSmithKline Consumer Healthcare AB	Ordinary		100	Nykaer 68, DK-2605, Brøndby, Denmark
GlaxoSmithKline Consumer Healthcare Australia Pty Ltd	Ordinary		100	82 Hughes Avenue, Ermington, NSW, 2115, Australia
GlaxoSmithKline Consumer Healthcare B.V.	Ordinary		100	Huis ter Heideweg 62, 3705 LZ, Zeist, Netherlands
GlaxoSmithKline Consumer Healthcare Colombia SAS	Ordinary		100	Avenida El Dorado, #69B-45/Piso 9, Bogota, Colombia

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
GlaxoSmithKline Consumer Healthcare Czech Republic s.r.o.	Ordinary		100	Hvezdova 1734/2c, Prague, 4 140 00, Czech Republic
GlaxoSmithKline Consumer Healthcare Finance Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Consumer Healthcare Finance No.2 Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Consumer Healthcare Finland Oy	Ordinary		100	Piispansilla 9A, Fin-02230, Espoo, Finland
GlaxoSmithKline Consumer Healthcare GmbH	Ordinary		100	Wagenseilgasse 3, Euro Plaza, Gebäude I, 4. Stock, Vienna, A-1120, Austria
GlaxoSmithKline Consumer Healthcare GmbH & Co. KG	Partnership Capital		100	Barthstr. 4, München, 80339, Germany
GlaxoSmithKline Consumer Healthcare Greece Societe Anonyme	Ordinary		100	274 Kifissias Avenue Halandri, Athens, 152 32, Greece
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC	LLC Interests		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GlaxoSmithKline Consumer Healthcare Holdings Limited	Ordinary A		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Consumer Healthcare Inc.	Common		100	7333 Mississauga Road North, Mississauga, ON, L5N 6L4, Canada
GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 3) Limited	Ordinary		100	Knockbrack, Dunganvan, Co Waterford, X35 RY76, Ireland
GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No.2) Unlimited Company	Ordinary		100	Knockbrack, Dunganvan, Co Waterford, X35 RY76, Ireland
GlaxoSmithKline Consumer Healthcare Investments (Ireland) Limited	Ordinary		100	6900 Cork Airport Business Park, Kinsale Road, Cork, County Cork, Ireland
GlaxoSmithKline Consumer Healthcare Ireland IP Limited	Ordinary		100	Curabinny, Carrigaline, County Cork, Ireland
GlaxoSmithKline Consumer Healthcare Japan K.K.	Ordinary		100	1-8-1 Akasaka Minato-Ku, Tokyo, Japan
GlaxoSmithKline Consumer Healthcare Korea Co., Ltd.	Ordinary		100	9F LS Yongsan Tower, 92, Hangang-daero, Yongsan-gu, Seoul, 04386, Korea, Republic of
GlaxoSmithKline Consumer Healthcare L.L.C.	LLC Interests		100	Corporation Service Company, 2595 Interstate Drive Suite 103, Harrisburg, Pennsylvania, 17110, United States
GlaxoSmithKline Consumer Healthcare Mexico, S. De R.L. de C.V.	Ordinary		100	Calzada Mexico-Xochimilco 4900, Colonia San Lorenzo Huipulco, Delegacion Tlalpan, Mexico, D.F. 14370, Mexico
GlaxoSmithKline Consumer Healthcare New Zealand Limited	Ordinary		100	Level 11, Zurich House, 21 Queen Street, Auckland, 1010, New Zealand
GlaxoSmithKline Consumer Healthcare Norway AS	Ordinary		100	Drammensveien 288, 1326 Lysaker, Norway
GlaxoSmithKline Consumer Healthcare Philippines Inc	Common		100	2266 Don Chino Rocas Avenue, Makati City, Philippines
GlaxoSmithKline Consumer Healthcare Pte. Ltd.	Ordinary		100	23 Rochester Park, 139234, Singapore
GlaxoSmithKline Consumer Healthcare S.A.	Ordinary		100	Site Apollo, Avenue Pascal 2-4-6, Wavre, 1300, Belgium
GlaxoSmithKline Consumer Healthcare S.A.	Ordinary		100	Severo Ochoa, 2, Parque Tecnológico de Madrid, Tres Cantos, Madrid, 28760, Spain
GlaxoSmithKline Consumer Healthcare S.p.A.	Ordinary		100	Via Zambelletti snc, Baranzate, Milan, 20021, Italy
GlaxoSmithKline Consumer Healthcare Saudi Limited	Ordinary		100	603 Salamah Tower 6th Floor, Madinah Road Al-Salamah District Jeddah 21425 Saudi Arabia
GlaxoSmithKline Consumer Healthcare Sdn. Bhd.	Ordinary		100	Lot 89, Jalan Enggang, Ampang/Ulu Kelang Industrial Estate, Selangor, 54200, Malaysia
GlaxoSmithKline Consumer Healthcare Slovakia s. r. o.	Ownership interest		100	Galvaniho 7/A, Bratislava, 821 04, Slovakia
GlaxoSmithKline Consumer Healthcare South Africa (Pty) Ltd	Ordinary		100	Flushing Meadows Building, The Campus, 57 Sloane Street, Bryanston 2021, South Africa
GlaxoSmithKline Consumer Healthcare Sp.z o.o.	Ordinary		100	Ul. Grunwaldzka 189, Poznan, 60-322, Poland
GlaxoSmithKline Consumer Healthcare Sri Lanka Holdings Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Consumer Healthcare SRL	Ordinary		100	1-5 Costache Negri Street, Opera Center One, 6th floor (Zone 2), District 5, Bucharest, Romania
GlaxoSmithKline Consumer Healthcare Vietnam Company Limited	Charter Capital		100	Floor 16, Metropolitan, 235 Dong Khoi, Ben Nghe Ward, District 1, Ho Chi Minh City, Viet Nam
GlaxoSmithKline Consumer Healthcare, Produtos para a Saude e Higiene, Lda	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal
GlaxoSmithKline Consumer Holding B.V.	Ordinary		100	Huis ter Heideweg 62, 3705 LZ, Zeist, Netherlands
GlaxoSmithKline Consumer Private Limited	Equity		100	Patiala Road, Nabha 147201, Dist Patiala, Punjab, India
GlaxoSmithKline Consumer Trading Services Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
GlaxoSmithKline Costa Rica S.A.	Ordinary		100	San Jose 300 Este de la Rotonda Betania, Carretera a Sabanilla, Costa Rica
GlaxoSmithKline d.o.o.	Quotas		100	Zmja od Bosne broj 7-7a, Sarajevo, 71000, Bosnia and Herzegovina
GlaxoSmithKline d.o.o.	Equity capital		100	Ulica Damira Tomljanovica Gavrana 15, Zagreb, Croatia
GlaxoSmithKline doo Beograd	Ordinary		100	Omladinskih brigada 88, New Belgrade, City of Belgrade, 11070, Serbia
GlaxoSmithKline Dungarvan Limited	Ordinary		100	Knockbrack, Dungarvan, Co Waterford, X35 RY76, Ireland
GlaxoSmithKline Ecuador S.A.	Ordinary		100	Av 10 De Agosto N36-239, y Naciones Unidas, Edificio Electroctuatoriana, 2do piso, Quito, Ecuador
GlaxoSmithKline Eesti OU	Ordinary		100	Lõõtsa 8a, Tallinn, 11415, Estonia
GlaxoSmithKline El Salvador S.A. de C.V.	Ordinary		100	Avenida El Boqueron y Calle Izalco No 7 y 8 Parque Industrial El Boqueron, Santa Elen, Antiguo Custatlan, La Libertad, El Salvador
GlaxoSmithKline EOOD	Ordinary		100	115 G Tsarigradsko Shose Blvd., floor 9, Mladost Region, Sofia, 1784, Bulgaria
GlaxoSmithKline Export Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Export Panama S.A.	Ordinary		100	Panama City, Republic of Panama, Panama
GlaxoSmithKline Far East B.V.	Ordinary		100	Huis ter Heideweg 62, 3705 LZ, Zeist, Netherlands
GlaxoSmithKline GmbH & Co. KG	Partnership Capital		100	Prinzregentenplatz 9, Munchen, 81675, Germany
GlaxoSmithKline Guatemala S.A.	Ordinary		100	Novena Avenida 0-09, Zona 4, Guatemala City, Guatemala
GlaxoSmithKline Healthcare AO	Ordinary		100	Presnenskaya nab 10, Moscow, 123112, Russian Federation
GlaxoSmithKline Healthcare GmbH	Ordinary		100	Barthstr. 4, München, 80339, Germany
GlaxoSmithKline Healthcare Ukraine O.O.O.	Ownership interest		100	Pavla Tychny avenue, 1-V, Kiev, 02152, Ukraine
GlaxoSmithKline Holding AS	Ordinary		100	Drammensveien 288, 1326 Lysaker, Norway
GlaxoSmithKline Holdings (Americas) Inc.	Common	100		Wilmington Trust SP Services Inc., 1105 North Market Street, Suite 1300, Wilmington, Delaware, 19801, United States
GlaxoSmithKline Holdings (Ireland) Limited	Ordinary; Deferred		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Holdings Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
GlaxoSmithKline Honduras S.A.	Ordinary		100	Tegucigalpa, MDC, Honduras
GlaxoSmithKline IHC Limited	Ordinary	100		980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline İlaclari Sanayi ve Ticaret A.S.	Nominative		100	Büyükdere Caddesi No. 173, 1.Levent Plaza B Blok, 1.Levent, Istanbul, 34394, Turkey
GlaxoSmithKline Inc.	Class A Common; Class C Preference		100	7333 Mississauga Road North, Mississauga, ON, L5N 6L4, Canada
GlaxoSmithKline Insurance Ltd.	Ordinary		100	19 Par-La-Ville Road, Hamilton, HM11, Bermuda
GlaxoSmithKline Intellectual Property (No.2) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Intellectual Property (No.3) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Intellectual Property (No.4) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Intellectual Property Development Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Intellectual Property Holdings Limited	A Ordinary; B Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Intellectual Property Limited	Ordinary; Deferred		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Intellectual Property Management Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline International Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Investigación y Desarrollo, S.L.	Ordinary		100	Severo Ochoa 2 Parque Tecnológico de Madrid, Tres Cantos, Madrid, 28760, Spain
GlaxoSmithKline Investment Holdings Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Investment Services Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Investments (Ireland) Limited	Ordinary		100	Currafinny, Carrigaline, County Cork, Ireland
GlaxoSmithKline Investments Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
GlaxoSmithKline K.K.	Ordinary		100	1-8-1 Akasaka Minato-Ku, Tokyo, Japan
GlaxoSmithKline Korea Limited	Ordinary		100	9F LS Yongsan Tower 92, Hangangdae-ro Yongsan-gu, Seoul, 04386, Republic of Korea
GlaxoSmithKline Latin America, S.A.	Ordinary		100	Panama City, Republic of Panama, Panama
GlaxoSmithKline Latvia SIA	Ordinary		100	Duntes iela 3, Riga, Latvia
GlaxoSmithKline Lietuva UAB	Ordinary		100	Ukmerges st. 120, Vilnius, LT-08105, Lithuania

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
GlaxoSmithKline Limited	Ordinary		100	Units 2201, 2214 and 23/F, Tower 6, The Gateway, 9 Canton Road, Harbour City, Tsimshatsui, Kowloon, Hong Kong
GlaxoSmithKline Limited	Ordinary		100	Likoni Road, PO Box 78392, Nairobi, Kenya
GlaxoSmithKline LLC	LLC Interests		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GlaxoSmithKline Manufacturing SpA	Ordinary		100	Via Alessandro Fleming 2, Verona, 37135, Italy
GlaxoSmithKline Maroc S.A.	Ordinary		100	42-44 Angle Bd, Rachidi et Abou Hamed El Glaza, Casablanca, Morocco
GlaxoSmithKline Medical and Healthcare Products Limited	Ordinary		100	H-1124, Csorsz utca 43, Budapest, Hungary
GlaxoSmithKline Mexico S.A. de C.V.	Ordinary A; Ordinary B		100	Calzada, Mexico-Xochimilco 4900, Colonia San Lorenzo, Huipulco, Delegacion Tlalpan, 14370, Mexico
GlaxoSmithKline NZ Limited	Ordinary		100	Level 11, Zurich House, 21 Queen Street, Auckland, 1010, New Zealand
GlaxoSmithKline Oy	Ordinary		100	Piispansilta 9A, P.O. Box 24, Espoo, FIN-02230, Finland
GlaxoSmithKline Panama S.A.	Ordinary		100	Urbanizacion Industrial Juan D, Calles A Y B, Republic of Panama, Panama
GlaxoSmithKline Paraguay S.A.	Ordinary		100	Oficial Gilberto Aranda 333, Planta Alta casi Salvador del Mundo, Asuncion, Paraguay
GlaxoSmithKline Peru S.A.	Ordinary		100	Av. Javier Prado Oeste, 995, San Isidro, LIMA 27, Peru
GlaxoSmithKline Pharma A/S	Ordinary		100	Nykær 68, Brøndby, DK-2605, Denmark
GlaxoSmithKline Pharma GmbH	Ordinary		100	Wagenseilgasse 3, Euro Plaza, Gebäude I, 4. Stock, Vienna, A-1120, Austria
GlaxoSmithKline Pharmaceutical Kenya Limited	Ordinary		100	L.R. NO. 209/6921, 5th Floor, Ilea Lion Centre, Riverside Park West Wing, Chiromo Road, Westlands P.O. Box 10643-00100, Nairobi, Kenya
GlaxoSmithKline Pharmaceutical Nigeria Limited	Ordinary		100	1 Industrial Avenue, Ilupeju, Ikeja, Lagos, PM B 21218, Nigeria
GlaxoSmithKline Pharmaceutical Sdn Bhd	Ordinary		100	Level 6, Quill 9, 112, Jalan Semangat, Petaling Jaya, Selangor Darul Ehsan, 46300, Malaysia
GlaxoSmithKline Pharmaceuticals (Pvt) Ltd	Ordinary		100	121 Galle Road, Kaldemulla, Moratuwa, Sri Lanka
GlaxoSmithKline Pharmaceuticals (Suzhou) Limited	Ordinary		100	No 40 Su Hong Xi Road, Suzhou Industrial Park, Suzhou, 215021, China
GlaxoSmithKline Pharmaceuticals Costa Rica S.A	Ordinary		100	300 metros al este de la Rotonda de la Betania, Mercedes de Montes de Oca, Sabanilla, Montes de Oca, San Jose, Costa Rica
GlaxoSmithKline Pharmaceuticals S.A.	Ordinary A; Ordinary B; Ordinary C; Ordinary D		100	Ul. Grunwaldzka 189, Poznan, 60-322, Poland
GlaxoSmithKline Pharmaceuticals SA	Ordinary		100	Site Apollo, Avenue Pascal 2-4-6, Wavre, 1300, Belgium
GlaxoSmithKline Pharmaceuticals Ukraine LLC	Chartered Capital		100	Pavla Tychyny avenue, 1-V, Kiev, 02152, Ukraine
GlaxoSmithKline Philippines Inc	Common		100	2266 Chino Roces Avenue, City of Makati, 1231, Philippines
GlaxoSmithKline Pte Ltd	Ordinary		100	23 Rochester Park, 139234, Singapore
GlaxoSmithKline Puerto Rico Inc.	Common		100	Centro Internacional de Mercadeo, 90 Road # 165, Tower II, Suite 800, Guaynabo, 00968, Puerto Rico
GlaxoSmithKline Republica Dominicana S.A.	Ordinary		100	Av. Lope de Vega No. 29, Torre Empresarial Novocentro, Local 406, Ensanche Naco, Santo Domingo, Distrito Nacional, Dominican Republic
GlaxoSmithKline Research & Development Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline S.A.	Ordinary		100	Severo Ochoa, 2, Parque Tecnológico de Madrid, Tres Cantos, Madrid, 28760, Spain
GlaxoSmithKline S.p.A.	Ordinary		100	Via Alessandro Fleming 2, Verona, 37135, Italy
GlaxoSmithKline s.r.o.	Ordinary		100	Hvezdova 1734/2c, Prague, 4 140 00, Czech Republic
GlaxoSmithKline Sante Grand Public SAS	Ordinary		100	23 rue François Jacob, 92500, Rueil-Malmaison, France
GlaxoSmithKline Services GmbH & Co. KG	Partnership Capital		100	Prinzregentenplatz 9, Munchen, 81675, Germany
GlaxoSmithKline Services Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GlaxoSmithKline SL Holdings, LLC	LLC Interests		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GlaxoSmithKline SL LLC	LLC Interests		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GlaxoSmithKline SL LP	Partnership		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Slovakia s.r.o.	Ordinary		100	Galvaniho 7/A, Bratislava, 821 04, Slovakia
GlaxoSmithKline South Africa (Pty) Limited	Ordinary		100	Flushing Meadows Building, The Campus, 57 Sloane Street, Bryanston 2021, South Africa

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
GlaxoSmithKline Trading	Ordinary		100	Leningradskiy Prospect, 37A, bld. 4, Moscow, 125167, Russian Federation
GlaxoSmithKline Trading Services Limited	Ordinary		100	Curraheen, Carrigaline, County Cork, Ireland
GlaxoSmithKline Tuketici Sagligi Anonim Sirketi	Nominative		100	Büyükdere Caddesi No. 173, 1. Levent Plaza B Blok, 1. Levent, Istanbul, 34394, Turkey
GlaxoSmithKline Tunisia S.A.R.L.	Ordinary		100	Immeuble Les Quatres R, Rue du Lac Lochness, Berges du Lac, Tunis, Tunisia
GlaxoSmithKline UK Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Uruguay S.A.	Registered shares provisory stock		100	Salto 1105, CP 11.200 Montevideo, Uruguay
GlaxoSmithKline US Trading Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GlaxoSmithKline Venezuela C.A.	Ordinary		100	Urbanizacion La Trinidad, Calle Luis De Camoems, Edif No 115-117 Apatado Posta, Caracas, 1010, Venezuela
GlaxoSmithKline Vietnam Limited Liability Company	Equity capital		100	The Metropolitan, 235 Dong Khoi Street, District 1, 7th Floor Unit 701, Ho Chi Minh City, Viet Nam
GlaxoSmithKline-Consumer Hungary Limited Liability Company	Membership		100	H-1124, Csorsz utca 43, Budapest, Hungary
GlycoVaxyn AG	Common; Preferred A; Preferred B; Preferred C		100	Grabenstrasse 3, 8952 Schlieren, Switzerland
Groupe GlaxoSmithKline S.A.S.	Ordinary		100	23 Rue François Jacob, 92500, Rueil-Malmaison, France
GSK Australia NVD Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
GSK Business Service Centre Sdn Bhd	Ordinary		100	Level 6, Quill 9, 112, Jalan Semangat, Petaling Jaya, Selangor Darul Ehsan, 46300, Malaysia
GSK Capital K.K.	Ordinary		100	1-8-1 Akasaka Minato-Ku, Tokyo, Japan
GSK CH Argentina S.A.	Nominative non endorseable ordinary shares		100	Tucumán 1, piso 4, Buenos Aires, C1049AAA, Argentina
GSK CH Kazakhstan LLP	Charter Capital		100	32 A Manasa Str., Bostandyk District, Almaty, 050008, Kazakhstan
GSK Commercial Sp. z o.o.	Ordinary		100	ul. Rzymowskiego 53, Warsaw, 02-697, Poland
GSK Consumer Health, Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GSK Consumer Healthcare Israel Ltd	Ordinary		100	25 Basel Street, Petech Tikva 49510, Israel
GSK Consumer Healthcare S.A.	Ordinary		100	Route de l'Etraz 2, 1197 Prangins, Switzerland
GSK Consumer Healthcare Schweiz AG	Ordinary		100	Suurstoffi 14, Rotkreuz, 6343, Switzerland
GSK Consumer Healthcare Services, Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GSK Consumer Healthcare Singapore Pte. Ltd.	Ordinary		100	23 Rochester Park, 139234, Singapore
GSK d.o.o., Ljubljana	Ordinary		100	Ameriška ulica 8, Ljubljana, 1000, Slovenia
GSK Finance (No 2) Limited	Ordinary	100		980 Great West Road, Brentford, Middlesex, TW8 9GS, England
GSK Kazakhstan LLP	Partnership Interest		100	273, N. Nazarbayev ave., Almaty, Medau District, 050059, Kazakhstan
GSK Pharmaceutical Trading SA	Ordinary		100	5 Poienelor Street, Brasov, Romania
GSK Services Sp z o.o.	Ordinary		100	Ul. Grunwaldzka 189, Poznan, 60-322, Poland
GSK Vaccines BV	Ordinary		100	Hullenbergweg 85, Amsterdam, 1101 CL, Netherlands
GSK Vaccines GmbH	Ordinary		100	Emil-von-Behring-Str.76, 35041 Marburg, Germany
GSK Vaccines Institute for Global Health S.r.l.	Quotas		100	Via Fiorentina 1, Siena, 53100, Italy
GSK Vaccines S.r.l.	Quotas		100	Via Fiorentina 1, Siena, 53100, Italy
GSK Vaccines Vertriebs GmbH	Ordinary		100	Rudolf-Diesel-Ring 27, Holzkirchen, 83607, Germany
HGS France S.a.r.l.	Ordinary		100	117 Avenue, Victor Hugo, Boulogne-Billancourt, 92100, France
Horlicks Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Human Genome Sciences, Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
ID Biomedical Corporation of Quebec	Common		100	2323 du Parc Technologique, Québec, PQ, G1P 4R8, Canada
ID Biomedical Corporation of Washington	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Instituto Luso Farnaco, Limitada	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquarque, Miraflores, Alges, 1495-131, Portugal
InterPharma Dienstleistungen GmbH	Quotas		100	Wagenseilgasse 3, Euro Plaza, Gebäude I, 4. Stock, Vienna, A-1120, Austria
Iodosan S.p.A.	Ordinary		100	Via Zambelletti snc, Baranzate, Milan, 20021, Italy
J&J Technologies, LC	LLC Interests		100	Corporation Service Company, Bank of America, 16th Floor, 1111 East Main Street, Richmond, Virginia, 23219, United States
Kuhs GmbH	Ordinary		100	Barthstr. 4, München, 80339, Germany
Laboratoire GlaxoSmithKline	Ordinary		100	23 rue François Jacob, 92500, Rueil-Malmaison, France

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
Laboratoire Pharmaceutique Algérien LPA Production SPA	Ordinary		100	Zone Industrielle Est, Boudouaou, Boumerdes, Algeria
Laboratoire Pharmaceutique Algérien SPA	Ordinary		100	Zone Industrielle Est, Boudouaou, Boumerdes, Algeria
Laboratoires Paucourt	Ordinary		100	23 rue François Jacob, 92500, Rueil-Malmaison, France
Laboratoires Saint-Germain	Ordinary		100	23 rue François Jacob, 92500, Rueil-Malmaison, France
Laboratorios Dermatologicos Darier, S.A de C.V.	Ordinary A; Ordinary B		100	Calzada Mexico Xochimilco, 4900 San Lorenzo Huipulco, District Federal Mexico, 14370, Mexico
Laboratorios Farmaceuticos Stiefel (Portugal) LTDA	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal
Laboratorios Stiefel de Venezuela SA	Ordinary		100	Calle Luis de Camoens, Edificio GlaxoSmithKline, No. 115-117, Urb. La Trinidad, Caracas, Venezuela
Laboratorios Stiefel Ltda.	Ordinary		100	Rua Professor Joao Cavalheiro Salem 1077, Guanulhos, Sao Paulo, Brazil
Laboratorios Wellcome De Portugal Limitada	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal
Maxinutrition Limited	Ordinary		100	55 Baker Street, London, W1U 7EU, England
Mixis Genetics Limited	Ordinary; Ordinary Euro		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Montrose Fine Chemical Company Ltd	Ordinary		100	Shewalton Road, Irvine, Ayrshire, KA11 5AP, Scotland
Montrose Pharma Company Limited	Ordinary Quota		100	H-1124, Csorsz utca 43, Budapest, Hungary
N.C.H. - Nutrition Consumer Health Ltd	Ordinary		100	14 Hamephalsim St, Petach Tikva, Israel
Okairos AG	Common; Preferred A; Preferred B		100	c/o OBC Suisse AG, Aeschenvorstadt 71, 4051, Basel, Switzerland
P.T. Sterling Products Indonesia	A shares; B Shares		100	Graha Paramita Building, 5th F, Jalan Denpasar Raya Blok D-2, Jakarta, 12940, Indonesia
Panadol GmbH	Ordinary		100	Barthstr. 4, München, 80339, Germany
Penn Labs Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
PT GSK Consumer Healthcare Indonesia	Ordinary		100	Graha Paramita 5th F, Jl. Denpasar Raya Blok D-2, Kuningan, Jakarta, 12940, Indonesia
PT. Bina Dentalindo	Ordinary		100	Gedung Graha Ganesha Lantai 3, Jl Raya Bekasi Km 17, No5, Jakarta Timur 13930, Indonesia
S.R. One International B.V.	Ordinary		100	Huis ter Heideweg, 62 3705, LZ Zeist, Netherlands
S.R. One, Limited	Units (Common)		100	Corporation Service Company, 2595 Interstate Drive, Suite 103, Harrisburg, Pennsylvania, 17110, United States
Setfirst Limited	Ordinary; Preference	100		980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Smith Kline & French Laboratories Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Smith Kline & French Portuguesa-Produtos Farmaceuticos, LDA	Ordinary Quota		100	Rua Dr Antonio Loureiro Borges No 3, Arquiparque, Miraflores, Alges, 1495-131, Portugal
SmithKline Beecham (Bangladesh) Private Limited	Ordinary		100	14, Topkhana Road, Segunbagicha, Dhaka 1000, Bangladesh
SmithKline Beecham (Cork) Limited	Ordinary		100	Curabinny, Carrigaline, County Cork, Ireland
SmithKline Beecham (Export) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham (H) Limited	Non-cumulative non-redeemables; Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham (Investments) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham (Manufacturing) Limited	Ordinary		100	Curabinny, Carrigaline, County Cork, Ireland
SmithKline Beecham (SWG) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham Biologicals US Partnership	Partnership Interest		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
SmithKline Beecham Egypt L.L.C.	Quotas		100	Amoun Street, El Salam City, Cairo, Egypt
SmithKline Beecham Farma, S.A.	Ordinary		100	Severo Ochoa, 2, Parque Tecnológico de Madrid, Tres Cantos, Madrid, 28760, Spain
SmithKline Beecham Inter-American Corporation	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
SmithKline Beecham Limited	Ordinary 6.25p	100		980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham Marketing and Technical Services Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham Nominees Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham Overseas Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham Pension Plan Trustee Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
SmithKline Beecham Pension Trustees Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham Pharma GmbH & Co KG	Partnership Capital		100	Prinzregentenplatz 9, Munchen, 81675, Germany
SmithKline Beecham Pharma Verwaltungs GmbH	Ordinary		100	Prinzregentenplatz 9, Munchen, 81675, Germany
SmithKline Beecham Pharmaceuticals (Pty) Limited	Ordinary		100	Flushing Meadows Building, The Campus, 57 Sloane Street, Bryanston 2021, South Africa
SmithKline Beecham Pharmaceuticals Co.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
SmithKline Beecham Port Louis Limited	Ordinary		100	C/o CIM Corporate Services Ltd, Les Cascades Building, Edith Cavell Street, Port Louis, Mauritius
SmithKline Beecham Research Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
SmithKline Beecham S.A.	Ordinary		100	Ctra de Ajalvir Km 2.500, Alcala de Henares, Madrid, 28806, Spain
SmithKline Beecham Senior Executive Pension Plan Trustee Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Stafford-Miller (Ireland) Limited	Ordinary		100	Clocherane, Youghal Road, Dungarvan, Co. Waterford, Ireland
Stafford-Miller Limited	Ordinary; Non-Cumulative Non Redeemable Preference		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Sterling Drug (Malaya) Sdn Berhad	Ordinary		100	Lot 89, Jalan Enggang, Ampang/Ulu Kelang Industrial Estate, Selangor, 54200, Malaysia
Sterling Products International, Incorporated	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Stiefel Consumer Healthcare (UK) Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Stiefel Distributors (Ireland) Limited	Ordinary		100	Finisklin Business Park, Sligo, Ireland
Stiefel Dominicana, S.R.L.	Ordinary		100	Ave. Lope de Vega #29, Torre NovoCentro, Local 406, Santo Domingo, Dominican Republic
Stiefel Farma, S.A.	Ordinary		100	Severo Ochoa, 2, Parque Tecnológico de Madrid, Tres Cantos, Madrid, 28760, Spain
Stiefel GmbH & Co. KG	Partnership Capital		100	Industriestrasse 32-36, Bad Oldesloe, 23843, Germany
Stiefel India Private Limited	Equity		100	401-402, A, Wing, 4th Floor, Floral Deck Plaza, Opp Rolta Bhavan, Central MIDC Road, Mumbai, Andheri (E), 400093, India
Stiefel Laboratories (Ireland) Limited	Ordinary		100	Finisklin Business Park, County Sligo, Ireland
Stiefel Laboratories (Maidenhead) Ltd	Ordinary		100	Eurasia Headquarters, Concorde Road, Maidenhead, Berkshire, SL6 4BY, England
Stiefel Laboratories (U.K.) Ltd	Ordinary		100	Eurasia Headquarters, Concorde Road, Maidenhead, Berkshire, SL6 4BY, England
Stiefel Laboratories Legacy (Ireland) Limited	Ordinary		100	Finisklin Business Park, Sligo, Ireland
Stiefel Laboratories Limited	Ordinary		100	Eurasia Headquarters, Concorde Road, Maidenhead, Berkshire, SL6 4BY, England
Stiefel Laboratories Pte Limited	Ordinary		100	103 Gul Circle, 629589, Singapore
Stiefel Laboratories, Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Stiefel Maroc SARL	Ordinary		100	275 Boulevard Zerktouni, Casablanca, Morocco
Stiefel Research (Australia) Holdings Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
Stiefel Research Australia Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
Stiefel West Coast LLC	LLC Interests		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Strebor Inc.	Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Tempero Pharmaceuticals, Inc.	Series A Preference; Series B Preference; Common		100	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
The Sydney Ross Co.	Common		100	Corporation Service Company, Princeton South Corporate Center, Suite 160, 100 Charles Ewing Blvd, Ewing, New Jersey, 08628, United States
The Wellcome Foundation Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
UCB Pharma Asia Pacific Sdn Bhd	Ordinary		100	Level 8, Symphony House, Pusat Dagangan Dana 1, Jalan PJU 1A/46, Petaling Jaya, Selangor Darul Ehsan, 47301, Malaysia

GlaxoSmithKline Finance plc

Notes to the financial statements for the year ended 31 December 2018

29 Subsidiaries and associated undertakings (continued)

Name	Security	Direct shares held (%)	Indirect shares held (%)	Registered Address
Vog AU PTY LTD	Ordinary; Redeemable Preference		100	82 Hughes Avenue, Ermington, NSW, 2115, Australia
Wellcome Consumer Healthcare Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Wellcome Consumer Products Limited	Ordinary		100	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Wellcome Developments Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
Wellcome Limited	Ordinary	100		980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Wellcome Operations Pty Ltd	Ordinary		100	1061 Mountain Highway, Boronia, VIC, 3155, Australia
Amoun Pharmaceutical Industries Co. S.A.E.	New Monetary Shares (99.5%)		90.7	El Salam City 11491, PO Box 3001, Cairo, Egypt
Beecham Enterprises Inc.	Common		88	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Biddle Sawyer Limited	Equity		75	252 Dr Annie Besant Road, Mumbai, 400030, India
Galvani Bioelectronics Inc.	Common		55	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Galvani Bioelectronics Limited	A Ordinary; B Ordinary (0%)		55	980 Great West Road, Brentford, Middlesex, TW8 9GS, England
Glaxo Saudi Arabia Limited	Ordinary		75	PO Box 22617, Area No 73 to 156, Warehouse City, First Stage Al Khomrah, Jeddah 21416, Saudi Arabia
Glaxo Wellcome Ceylon Limited	Ordinary; Ordinary B		99.6	121 Galle Road, Kaldemulla, Moratuwa, Sri Lanka
GlaxoSmithKline (Tianjin) Co. Ltd	Ordinary		90	No. 65, the Fifth Avenue, Tai Feng Industrial Park, Tianjin Economic and Technological Zone, 300457, China
GlaxoSmithKline Algérie S.P.A.	Ordinary		99.99	Zone Industrielle Est, Boudouaou, Wilaya de Boumerdes, Algeria
GlaxoSmithKline Bangladesh Limited	Ordinary (82%)		82	Fouzderhat Industrial Area, Dhaka Trunk Road, North Kattali, Chittagong - 4217, Bangladesh
GlaxoSmithKline Consumer Healthcare Limited	Ordinary		72.5	Patiala Road, Nabha 147201, Dist Patiala, Punjab, India
GlaxoSmithKline Consumer Healthcare Pakistan Limited	Ordinary (85.8%)		85.8	35 Dockyard Road, West Wharf, Karachi, 74000, Pakistan
GlaxoSmithKline Consumer Healthcare, L.P.	Partnership Capital		88	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
GlaxoSmithKline Consumer Nigeria plc	Ordinary (46.4%)		46.4	1 Industrial Avenue, Ilupeju, Ikeja, Lagos, PM B 21218, Nigeria
GlaxoSmithKline OTC (PVT.) Limited	Ordinary		85.8	The Sykes Building, 35 Dockyard Road, West Wharf, Karachi, 74000, Pakistan
GlaxoSmithKline Pakistan Limited	Ordinary (82.6%)		82.6	35 Dockyard Road, West Wharf, Karachi, 74000, Pakistan
GlaxoSmithKline Pharmaceuticals Limited	Equity (75%)		75	252 Dr Annie Besant Road, Mumbai, 400030, India
GlaxoSmithKline S.A.E.	Ordinary (91.2%)		91.2	Boomerang Office Building - Land No. 46, Zone (J) - 1st District, Town Center - 5th Tagammoe, New Cairo City, Egypt
GSK-Gebro Consumer Healthcare GmbH	Ordinary		60	Bahnhofbühl 13, 6391 Fieberbrunn, Kitzbühel, Austria
Modem Pharma Trading Company L.L.C.	Quotas (98.2%)		98.2	Amoun Street, PO Box 3001, El Salam City, Cairo, 11491, Egypt
P.T. SmithKline Beecham Pharmaceuticals	A Shares; B Shares (0%)		99	Jl. Pulobuaran Raya, Kav. III DD/2,3,4, Kawasan Industri Pulogadung, Jakarta, 13930, Indonesia
PT Glaxo Wellcome Indonesia	A Shares; B Shares (0%)		95	Jl Pulobuaran Raya Kav III DD/, Kawasan Industri Pulogadung, Timur, Jakarta, 13930, Indonesia
Sino-American Tianjin Smith Kline & French Laboratories Ltd	Ordinary (55%)		55	Cheng Lin Zhuang Industrial Zone, Dong Li District, Tianjin, 300163, China
SmithKline Beecham (Private) Limited	Ordinary (99.6%)		99.6	World Trade Center, Level 34, West Tower, Echelon Square, Colombo 1, Sri Lanka
SmithKline Beecham-Biomed O.O.O.	Participation Interest (97%)		97	Leningradskiy Prospekt, 37A, bld. 4, Moscow, 125167, Russian Federation
Stiefel Egypt LLC	Quota (99%)		99	Amoun Street, El Salam City, Cairo, Egypt
Winster Pharmaceuticals Limited	Ordinary		46.4	2A Association Avenue, Ilupeju Industrial Estate, Lagos, PO Box 3199, Nigeria
Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.	Ordinary		95	No. 56, Tian He Road, Yuhang Economic Development Zone, Hangzhou, Zhejiang Province, China
Chiron Panacea Vaccines Private Limited	Equity Shares (50%)		50	708/718, 7th Floor, A Wing, Sagar Tech Plaza, Saki Naka, Andheri East, Mumbai, Maharashtra, 400072, India
Japan Vaccine Co., Ltd.	Ordinary		50	6 Yonbancho, Chiyoda-ku, Tokyo, Japan
Japan Vaccine Distribution Co., Ltd.	Ordinary		50	6 Yonbancho, Chiyoda-ku, Tokyo, Japan
Qualivax Pte. Limited	Ordinary		50	80 Robinson Road, #02-00, 068898 Singapore
Quell Intellectual Property Corp., LLC	Membership Interest		50	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States
Qura Therapeutics, LLC	Units		50	Corporation Service Company, 251 Little Falls Drive, Wilmington, Delaware, 19808, United States